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Abstract 
Although it is more than 100 years since Robert Koch discovered the tubercle 
bacillus, and more than 40 years since effective chemotherapy became available, 
tuberculosis remains a major cause of morbidity and mortality in the world to-day. A 
major contributor to the morbidity is anaemia. This anaemia falls under the 
classification of anaemia ~f chronic disorders, the pathogenesis of which has not been 
fully elucidated. With the advent of recombinant human erythropoietin (Epo ), it has 
become evident that a blunted Epo response to the anaemia plays a major role. The 
mechanism (s) involved still have to be elucidated. 
The aims of ,this study were to evaluate serum Epo levels and iron parameters in 
anaemic patients with active pulmonary tuberculosis (PTB) and investigate the effect 
of tumour necrosis factor alpha (TNFa) produced by activated macrophages in PTB 
patients on Epo production in vitro. Furthermore the mechanism involved in Epo 
gene expression was investigated. 
Haematological and biochemical parameters ( including serum iron and Epo) were 
I 
studied prospectively in four groups eacq of 1 O subjects. Group I comprised newly 
diagnosed non-pregnant individuals with pulmonary tuberculosis (PTB), 
haemoglobin below 110 g/L, and having no apparent dissemination or other 
I 
associated systemic illnesses. Group II were age and sex matched PTB patients with 
haemoglobin levels greater than 130 g/L. Group III ·consisted of otherwise healthy 
' people with demonstrated absolute iron deficiency anaemia with haemoglobin 
corres~onding to those in Group I. Group IV consisted of 10 healthy non-anaemic 
volunteers. For matching degrees of anaemia, the serum Epo was significantly lower 
in Group I than in Group III patients. In PTB, therefore, the Epo response to 
anaemia is attenuated. With anti-tuberculous therapy there was a significant increase 
in the Hb and serum iron levels in the Group I patients which correlated with a fall in 
the levels of the inflammatory marker C-reactive protein (CRP). This argues for the 
degree of inflammation being casually related to the anaemia. 
V 
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To further investigate the effect of inflammation on Epo production, blood samples 
were collected . from individuals in Groups I, II and III and the peripheral blood 
mononuclear cells (I>BMC) were assayed for the cytokine TNFa. The incubation of 
supernatant fractions (SNF) of the anaemic PTB group with HepG2 cells resulted in a 
marked inhibition of Epo production by these cells .. Dose response studies showed 
that increasing concentration of SNF resulted in a progressive reduction in Epo 
production, which could be reversed by the presence of anti-TNFa antibodies in the 
: 
medium. Thus TNFa is capable of inhibiting Epo production and may play a role in 
the blunted Epo response to anaemia seen in patients with PTB. 
In order to characterize the mecha~isms involved in oxygen sensing, the murine Epo 
gene was studied to define the sequences within the enhancer involved in oxygen 
sensing and Epo gene expression. To this end, transfection experiments of deleted, 
mutated and re-iterated enhancer sequences located 3' to the poly (A) signal sequence 
were carried out in HepG2 cells and in the non-Epo producing lung fibroblastoid cell 
line a23. Transcription factor binding to the ~nhancer was investigated by DNA 
I 
footprint analysis and revealed that at least thr~e sites within a 96 nucleotide sequence 
0f the Epo enhancer were critical. Oxygen regulated operation was dependent on sites 
' ' 
within the first 25 nucleotides. In both HepG2 and a23 cell lines the same two critical 
sites in the 5' region of the enhancer were necessary for function. Sequences located 
3' to this region modulated enhancer function but did not themselves convey oxygen 
regulated operation. 
This study has contributed to the understanding of the pathophysiology of the 
I 
ana~mia of tuberculosis in that in this disease, TNFa released from activated 
macrophages was capable of inhibiting Epo production in vitro. This may explain the 
attenuated Epo response to anaemia in PTB patients. Furthermore three critical sites 
on the Epo enhancer were shown to be essential for oxygen sensing and Epo gene 
expression. It can be postulated, therefore, that TNFa may disrupt the interaction of 
transcription factors with critical sites of oxygen sensing on the enhancer and prevent 





Inflammation may be defined as the organism's resppnse to injury irrespective of the 
aetiology. Although this is to protect the host, certain negative consequences may 
ensue. Mild or moderate anaemia, for example, frequently accompanies such diverse 
disorders as tuberculosis, rheumatoid arthritis, Crohn's disease and cancer. This is 
probably the commonest form of anaemia encountered in hospital practice and has 
characteristic morphologic, biochemical and kinetic alterations and is termed a~aemia 
of chronic disorders. 
Haematological changes associated with pulmonary tuberculosis have been 
incompletely investigated in that only the prevalence and severity have been 
documented and no work has been carried out on the pathophysiology of the disease. 
The purpose of this review is to encompass a spectrum of clinical and scientific 
publications with respect to the epidemiology, immunopathogenesis of tuberculosis and 
I , ' 
report on studies carried out to elucidate the pathophysiology of anaemia of chronic 
disorders and particularly the role of erythropoietin in this regard . 
1.2 TUBERCULOSIS.· 
1.2.1. Epidemiology: 
Globally the incidence of tuberculosis (TB) is rising rapidly : 1. 7 billion -people are 
infected with Mycobacterium tuberculosis world-wide, with 8 million new cases of the 
disease and almost 3 million deaths occurring annually (1). 
1 
Chapter1 Literature Review 
This has led the World Health Organization (WHO) to take the unprecedented step of 
declaring TB a global emergency. This is in itself an ominous statement and, have 
suggested that four major elements have played a role in the creation of the global TB 
emergency (2). These included the following :-
• Poor quality TB control programmes which fail to cure but keep infectious patients 
alive, thus increasing the infectious pool in the community. -
• The HIV epidemic !which has the propensity of worsening the situation dramatically 
• Socioeconomic trends of the past few decades, including increased immigration, 
influx of refugees and economic recession, resulting in cuts in public spending with 
deterioration of public health services and increasing poverty. The relative 
I . 
importance of these elements obviously differs in industrialised and developing 
countries. 
• Demographic changes ( decreased child mortality with a consequent increase in the 
number of people over 15 years of age, many of whom were infected with TB as 





In South Africa, as in pther sub-Saharan African States, poor quality TB control 
j I 
programmes, HIV infection and demographic changes are important factors in the 
rapid rise in tuberculosis (3) . The Western Cape, the area where this study was carried 
out, has the highest incidence of TB in the whole of South Africa, at 702.6/100,000 
(Figure 1.1) ( 4 ). Furthermore ethnic differences exist in the incidence of TB, with the 
' . 
coloured population having an incidence rate which is progressively increasing 
compared to the other population groups (Table 1.1 ). However, there are no South 
African data which indicate that the col?ured population have increased genetic 
susceptibility to activation of latent TB infection. Thus the cause for the geographic 
and ethnic distribution of TB in South Africa is as yet unknown. 
2 
Figure 1.1: Demographic distribution of tuberculosis in South Africa as on 25/01/95 
D 0,0 · 100,0 
1111111111 100, 1 · 200,0 y 
film 200, 1 - 400,0 Province Cases Population IR 
D 400, 1 - 600,0 Eastern Cape 17870 6368655 280,59 
• 600, 1 · 800,0 
Eastern Transvaal 2401 2853212 84,15 
Gauteng 12969 6757225 191,93 
KwaZulu/Natal 9695 8409594 115,28 
Northern Cape 3130 750271 417,18 
Northern Transvaal 2654 4993798 53,15 
North West 2731 3292393 82,95 
Orange Free State 12990 2751972 472,03 
IWestem Cape 24858 3537980 702,60! 
South Africa 89298 39715010 224,85 
Outside South Africa 439 
Total 89737 
IR= Incidence Rate/100000 
Adapted from Tuberculosis Update (from ref 4) 
Table 1.1 The incidence rate (IR) per 100 000 population of tuberculosis per 
population group, South Africa, 1990 - 1994 (as on 23/01/95) 
I 
Population 1990 1991 1992 1993 
Group Cases Population IR Cases Population IA Cases Population IA Cases Population IR 
Asian 580 975994 59,43 547 990994 55,20 558 1005994 55,47 519 1021994 50,78 
Black 59093 27931168 211 ,57 54481 28664884 190,06 58205 29407593 197,93 62293 30154302 206,58 
!Coloured 19604 3245745 603,99 21501 3296667 652,20 22172 3346586 662,53 24201 3396505 712,53 
White 882 5037947 17,51 810 5073300 15,97 i 967 5108254 18,93 964 5142209 18,75 
Unknown 49 154 3?7 1321 
Total 80208 37190854 215,67 77493 38025845 203,79 82299 38868427 211,74 89298 i 39715010 224,85 
Adap:ted from Tuberculosis Update (from ref 4) 
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1.2.2 Immunopathogenesis of Tuberculosis : 
On entry into the immunocompetent body the tubercle bacilli are processed by 
macrophages and then expressed on their cell membranes in conjunction with the class 
II major histocompatibility complex antigen (HLA-DR). This complex binds with the 
T-Cell antigen receptor (TCR) in T lymphocytes and, together with a second signal of 
interleukin- I (IL-1) secreted from the macrophage generates the specific immune 
response (Figure 1.2) (5). In this way the T ~lymphocytes become 'activated' dividing, 
expressing several surface receptors and secreting a variety of immune modulators 
called cytokines. The cytokines attract macrophages and lymphocytes to the . site of 
infection, and these macrophages' become 'activated', enlarging and be~orning more . 
efficient at phagocytosis and killing. Some macrophages are transformed into more 
specialised forms eg. epitheloid cells (more secretory than pha:gocytic) and multi-
nucleated giant cells. The aggregation of these macrophages and lymphocytes results in 
the characteristic granuloma of tuberculous infection. 
I 
An individual newly infected with M. tuberculosis only has a 2 - 5% risk of developing 
, I 
, active disease following primary infection and i an approximate 10% lifetime risk of 
I 
developing post-primary tuberculous disease (6). Thus, there is an enormous gap 
between infection on the one hand and disease on the other, and the vast majority, up 
to 98%, have no difficulty in mounting a highly effective protective immune response 
that completely suppresses ,and perhaps even eradicates this infection . . 
4 
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Figure 1.2: Specific acquired immunity: Macrophage together with MHC II presents the antigen 
(mycobacterium) to the T lymphocytes. This results in release of various cytokines 
causing lymphocyte proliferation and further macrophage activation. \ 
(Adapted from ref 5) 








+ other lymphokines I 







Tly = T lymphocyt~s 
IL 1 = Interleukin 1 
IL2 = Interleukin 2 
TNFa= Tumor necrosis factor 
IFNy = Gamma interferon 
T3 = CD3 
TCR = T cell receptor 
Class II MHC MHC = Major histocompatability 
complex 
Rece~tly, researches have investigated the reasons why most people contain 
I 
tuberculous infection and why others develop disease. Mycobacteria causes two 
differJnt immune responses which were previously thought to be inextricably .linked: 
delayed hypersensitivity with tissue damage (Koch phenomenon) and protective 
cellular immunity. Recent immunological studies in vitro (7), have shown that there are 
. I • 
two distinct responses which can be separated, giving important clues to the variability 
in host responses to tuberculosis. 
Once an infection has been established, resistance to the progression from infection to 
disease requires a full-b1own cell-medicated immune response, which depends on T-
Cells. The T-helper subset of lymphocytes, bearing the CD4 ( cluster differentiation 
antigen) surface marker, recognise antigen that is presented by antigen-presenting cells 
such as macrophages in the context of major histocompatibility (MHC) class II 
5 
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molecules (Figure 1.3) (8) . Once activated the T-helper cells response is polarised 
between the so-called Th 1 and Th 2 divisions, which are primarily distinguished from 
one another in their profiles of secreted cytokines (Figure 1.4). The distinction between 
T-helper cells of Th 1 and Th 2 types is a recent and important advance in the 
understanding of protective immunity in infections (9). The Th 1 cells secretes in 
particular interferon gamma (IFNy) which contributes to the developments of cell 
mediated immunity with activation of macrophages and enhancement of cytotoxic 
cells. On the other hand, the Th 2 cell secrete predominantly interleukin 4 (IL-4) which 
antagonises most of the effects of IFNy and this inhibits the cell mediated response. It 
is likely that a shift from a Th 1 to Th 2 response in TB will lead to a failur·e of 
protective immunity and may be a factor in progressive tuberculous disease (10). 
Figure 1.3: Major histocompatability (MHC) class II processing and presentation 
of M.t.b antigens. Antigens derived from bacilli resident in phagosomes 
are processed and associate with MHC class II molecules. These are 
then transported to the cell surface where they are "read" by T ~ells of the 
CD4+ T helper (TH) suset. The T cell receptor (TCR) in associ13-tion with 
CD4 binds to the MHC II-antigen complex, thereby stimulating the TH cell. 
I -
Macrophage 
Adapted from Tuberculosis/HIV - Proceedings of an update conference. 
University of Stellenbosch, Cape Town, 1995. 
6 
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1.2.3 Tumour Necrosis Factor alpha and Tuberculosis : 
Tumour necrosis factor alpha (TFNa) also referred to as cachectin was discovered 
during studies of rabbits infected with Trypanosoma brucei that exhibited extreme weight 
loss, depletion of body mass and hypertriglyceridaemia. Rouzer _and Cerami ( 11) found 
that elevated serum levels of triglycerides were caused by suppression of lipoprotein 
i 
lipase (LPL). Subsequent work showed that mice infected with endotoxin produced a 
transferable serum factor that causes LPL suppression (12). This factor was successfully 
isolated by Beutler and others (13), and the name "cachectin" was given because of its 
suspected role as a mediator of cachexia. The role of,TFNa in tuberculosis is paradoxical 
because although there is much evidence for a protective role, there is much evidence 
that it plays a part in tissue damage that characterises human disease. 
Studies in the mouse, usmg gene knockout or neutralising antibodies, indicate that 
protection from M. Tb is mediated by a type 1 response. That is, it requires a Th 1 
I 
pattern of helper activity with secretion of IFNy, accompanied by w-IC I restricted 
functions, presumably CD
1
8+ cytotoxic T cells (14). Together these cell types can 
I 
activate macrophages and 
I 
perhaps kill infected cells that are failing to eliminate the 
bacilli. Experiments with neutralising antibodies indicate that TNFa is an essential 
component of the process (15). This may reflect the ability of the cytokine to trigger . . 
further killing mechanisms, such as nitric oxide production; in macrophages previously 
activated by IFNy (16) or it may be something to do with the putative role of TNFa in 
the organisation of granulomata (15). 
7 
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Adapted from Tuberculosis and HIV/AIDS - Proceedings of an Update 
Conference. University of Stellenbosch, Cape Town, 1995. 
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On the other hand, TNFa plays a role in the tissue damaging immunopathology that is 
characteristic of TB. The fever, weight loss and tissue injury that characterises 
advancedTB may be attributable in part to TNFa (17). This is probably due to 
stimulation of the release of collagenase from human synovial cells and dermal 
fibroblasts, by TNFa, which possibly contributes to tissue destruction and 
remodelling(l 8) . 
A potential resolution of this paradox emerged when Hernandez-Pando and Rook (19) 
showed that murine spleen cells when immunised with a dose of mycobacterium that 
produced a 'pure' Th 1 response, TNFa acted as an additional macrophage activating 
I 
factor without precipitating necrosis. However a dose of mycobacterial immunogen 
that produced a mixed Th 1 and Th 2 response caused tissue damage. This mixed 
pattern is characteristic of tuberculosis, and of the late stage of many chronic infections 
where elimination of the infecting organism is failing and chronic tissue damage is seen. 
It has been suggested that immunological manipulations which eliminate the Th 2 
! 
component, and boost the Th 1 response lmay allow the immune system to play a more 
I 
useful role in treatment of the disease (20~. 
I 
1.2.4 Anaemia of Tuberculosis: ' 
Haematological changes associated with pulmonary tuberculosis (PTB) have been 
incompletely investigated in that only the prevalence and severity have been reported 
and no work has yet been carried out to elucidate the pathophysiology of the anaemia 
associated with the disease. 
Baynes et al (21) evaluated 59 patients with active PTB ~n terms of haematological 
indices, iron related measurements and markers of inflammation. They found that 
anaemia was present in 76 % of patients with active PTB and in these patients the 
serum ferritin was raised which correlated with the degree of inflammation as measured 
by the C-reactive protein. In addition, there was a good correlation between serum 
ferritin and non-haem iron in the marrow. 
9 
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They concluded that although iron is diverted to the reticuloendothelial system, in 
active PTB, there was no evidence to suggest that the anaemia was secondary to iron-
deficient erythropoiesis as the percentage saturation of iron was 30%. 
Morris et al (22) studied the extent and severity of haematological and biochemical 
abnormalities in 265 patients with PTB. They showed that anaemia (Hb <11 g/dl, 
normochromic and normocytic) was present in 60% of patients and more frequently in 
males than in females . Serum ferritin, vitamin B 12 levels were elevated in 57% of 
subjects, whilst serum and red ceJl folic acid were within normal limits in the majority 
of patients. With anti-tuberculous therapy, there was a significant increase in the mean 
haemoglobin level from 11 g/dl to 12.3 g/dl at three months when sputa became acid 
fast bacilli negative. Important biochemical changes noted were hyponatraemia and 
hypoalbuminaemia. 
From these studies it can be seen that the anaemia of PTB can be classified as anaemia 
of chronic disorders in that the anaemia is mild, with a raised serum ferritin . In order to 
understand possible pathopryysiological mechanisms 9f this anaemia studies involving 
other examples of anaemia of chronic disorders will be reviewed. 
1.3. ANAEMIA OF CHRONIC DISORDERS 
I 
1.3.1 Description of the anaemia: 
In his classic review in 1966; Cartwright (23) defined the anaemia of chronic disorders 
(ACD) as follows : 
"The anaemia is usually mild in the degree, not progressive in the severity and is 
· characterised by a low plasma iron, decreased total iron binding capacity, decreased 
saturation of transferrin with iron, decreased bone marrow sideroblasts, normal or 
increased reticuloendothelial iron, increased plasma copper and increased free 
erythrocyte protoporphyrin.". 
10 
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Although the anae1TI1a 1s characteristically normochromic, hypochromia and 
microcytosis are seen when the serum iron concentration and more particularly the 
transferrin saturation are reduced (24). 
Iron deficient erythropoiesis occurs when the percentage saturation of transferrin falls 
below 16% but this occurs uncommonly in ACD (25). Furthermore, with the fall in 
serum iron and transferrin saturation there is a marked increase in serum ferritin - a 
finding which is the most convenient way of distinguishing ACD from iron deficiency 
anaemia (26) . 
I 
Other biochemical changes occur in ACD, including synthesis of new proteins such as 
C-reactive protein (27), decreased levels of albumin and transferrin . (28) and an 
augmented synthesis of fibrinogen (29), which may account for the accelerated 
erythrocyte sedimentation rate (ESR)(23). Bone marrow morphology is generally 
normal although there may be a degree of erythroid hypoplasia and defective red cell 
haemoglobinization. The most characteristic finding !on bone marrow examination, 
I 
I 
however, is a reduction in the number of siderobfasts while the reticulo-endothelial 
i i 
system (RES) iron deposits are normal or even increased (30) . 
1.3.2 Pathogenesis: 
Early investigators proposed that , three processes were involved in the production of 
this anaemia: 
• a modest shortening in red cell survival 
• disturbance in iron metabolism 
• impaired erythropoietin (Epo) production 
11 
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1. Haemolysis: 
The abnormal processes resulting in reduced erythrocyte survival have not been clearly 
defined. Two mechanisms by which this might occur have been proposed: 
Cartwright (23) favoured the hypothesis that the reticuloendothelial system (RES) 
became hyperactive in removal of red cells from the circulation. This increased 
phagocytic activity of the RES was presumably related to macrophage activation (31 ), 
the activation process being partly related to lymphokines released by immunologically 
cdmmitted lymphocytes (32) . These changes . are associated with greatly increased 
clearance rates for erythrocytes sensitised with antibodies (33) . Antibodies coating 
erythrocytes in amounts too small to produce changes in red cell survival in normal 
animals lead to dramatic increased in red cell destmction in animals with activated 
macrophages. Similarly, enhanced removal of red cells midly damaged with heat has 
been observed in animals given endotoxin (34). However, these studies employed 
damaged or sensitised red cells and uncertainty remains as to the applicability of these 
findings to normal cells. 
I 
When fever and inflammation were induced m rabbits by injections of bacterial 
endotoxin, excess destmction ofred cells occurred (35) . Although the injections might 
have produced their effects indirectly, for example, by stimulation of the macrophage 
system, experiments in heating chambers . showed that the destmction qf red cells was 
primarily due to idcreased temperature and erythrocyte damage preferentially affected 
the older segment of the red cell population (36). These studies support the hypothesis 
that fever may damage the membrane of older erythrocytes and that such damage may 
; 
play a role in the excessive destmction of red cells observed in ACD. However, 
reticulocyte counts are variable in ACD, thus there is universal agreement that the 
modest haemolysis seen in ACD is not a major contributing factor to the anaemia (37) . 
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2. Disturbances in Iron Metabolism: 
The characteristic feature of ACD is hypoferraemia despite iron stores that are either 
normal or raised. Cartwright (23) showed that there was a negative correlation 
between the level of serum iron and disease activity. Measures to suppress the 
inflammatory process in chronic disease have been followed by a sharp rise in serum 
iron levels (38,39). 
The fact that iron stores may be plentiful even if erythrocytes showed signs . of iron 
deficient erythropoiesis, lead to the postulate by Cartwright ( 40) that this was due to a 
block in the release of iron from the RES to the erythron. In a study of dogs, Fillet et al 
( 41) found that iron was released from he RES in two phases, a rapid one taking place 
within hours, and a slower one taking place over several days. Furthermore, they 
showed that acute inflammation was associated with abolition of the first rapid phase, 
thus providing some support for Cartwright's postulate of blocked RES iron release. 
In a study in man, Bentley et al ( 42) could not demonstrate this dual release mechanism 
I 
and found no evidence of a blocked RES iron release in nine patients with rhe~matoid 
' i i 
arthritis. Similarly Baynes et al (21) studying patients with active pulmonary 
tuberculosis showed that although iron is diverted to the RES, there was no evidence 
to suggest that the anaemia was due to iron deficient .erythropoiesis, as the percentage 
saturation of iron in the anae~c pulmonary tuberculosis group was 30%. These 
investigators postulated therefore, that the plentiful iron stores in ACD were not due to 
blocked RES iron release but were secondary to diminished use of iron due to a 
primary defect in erythropoiesis: 
Lactoferrin is an iron binding protein found m large quantities m the secondary 
granules of neutrophilic granulocytes and is released into the plasma during an 
inflammatory process. Its affinity for iron is greater than that of transferrin, especially 
at low pH ( 43 ), and it is taken up rapidly by macrophages ( 44). 
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Bacteria require significant quantities of iron for metabolism and replication ( 45). The 
movement of iron out of plasma augments the resistance of the host to invading 
bacteria (46). Studies carried out by Van Snick et al (47,48,49) suggested that 
lactoferrin might bind iron in extracellular fluid and transfer it to ferritin, predominantly 
I 
in RE cells. This would be entirely in keeping with its postulated antimicrobial activity. 
Thus the theory is interesting, but still unproven. Furthermore, even if it may apply to 
the anaemia of acute bacterial infection, in which plasma lactoferrin is high (50), this 
mechanism could hardly explain the hypoferraemia in rheumatoid arthritis, in which 
plasma lactoferrin is normal (51). 
Serum ferritin · increases during inflammation. This may be due to an acute phase 
response (52) or to a leak from cells whose membranes have been damaged by 
inflammation (53,54). Serum ferritin is glycosylated whereas intracellular ferritin is not 
(55). Thus it has been resolved that the raised serum ferritin seen in inflammation is the 
result of increased synthesis and not leakage from damaged cells (56) . 
Furthermore, it has b~en shown that , the increased synthesis of ferritin by the liver in 
• i 
an~mals with inflammation occurs before the fall in serum ir~n (57). Macrophages have 
also been shown to synthesise ferritin in response to inflammation and with the 
increased ,synthesis there was an increased uptake of iron by these cells (Figure 1.5) 
(58). 
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Figure 1.5: Influence of activated macrophages and specific cytokines, interferon (I FN) 
gamma and tumour-necrosis factor (TNF) alpha. on iron metabolism 
and haematopoiesis. (Adapted from ref 58) • 
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The impaired iron mobilisation: may also result from effects of cytokines. Denz et al 
(59) have reported a correlation between the immune activation marker neopterin and 
increasing ferritin levels in patients with malignancies, suggesting a role of immune 
activation in altered iron metabolism. Rogers et al (60) showed that interleukin-I (IL-
1) increased tran~lation of ferritin mRNA and this additional ferritin could act as a trap 
for iron that might otherwise be available for erythropoiesis. Moldawer et al ( 61) and 
Alvarez-Hernandez et al (62), reported that rodents injected with recombinant TNF 
develop a hypoferraemic anaemia associated with impaired iron release and 
incorporation into erythrocytes. · 
Studies of the biology of the cellular transferrin receptors (TfR) yielded additional 
insight into the · mechanisms by which inflammatory response may alter · iron 
metabolism. Graziadei and colleagues (63) reported that acute phase reactants such as 
a-1-antitrypsin inhibited erythropoiesis by impairing transferrin binding to TfR and 
subsequent internalisation of TfR-transferrin complex. Study of the cellular TfR has 
also provided clinically diagnostic assistance in ACD. TfR are increased in iron 
deficiency anaemia but is normal in ACD, providing a useful method to distinguish 
these often confused syndromes (64). 
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3. Relative Deficiency of Erythropoietin: 
The recognised role of Epo in the pathogenesis of ACD is becoming increasingly 
evident. However, before the studies are reviewed, physiological and biochemical 
aspects of the hormone will be discussed. 
1.4 ERYTHROPOIETIN 
1.4.1 Historical Background: 
In 1906 Carnot & DeFlandre (65) gave the name "hemopoietine" to a humoral factor 
that was thought to control red blood cell production. Later this hormone was more 
appropriately named "erythropoietin", implying restricted action of the hum oral factor 
on red blood cell production, by Bonsdorff and Jalavisto (66). Erslev in 1953 (67) 
provided definitive evidence of the existence of erythropoietin when he demonstrated 
the occurrence of reticulocytosis in rabits infused with large volumes of plasma from 
severely anaemic donor rabbits. In fact, Erslev predicted then, the potential therapeutic 
value of erythropoietic factor once available in purified form. Shortly thereafter, other 
investigators succeeded in demonstrating erythropoietic activity in plasma (68,69) and 
urine from anaemic 1rabbits (70). 
1.4.2 Structure of Erythropoietin: 
· . The human urinary Epo, purifi,ed to apparent homogeneity by Miyake et al in 1977 
. ,' ' 
(71), consisted of two fractions (a and~) ofsimilar biblogical activity, molecular mass, 
and. aminoacid sequence but different electrophoretic mobility and carbohydrate 
composition.The :native molecular mass of the polypeptide chain is 18 kDa (72), while 
the glycosylated form has a molecular mass of 30 kDa (73) Human urinary and 
recombinant DNA-derived Epo are identical with regard to amino acid sequence, 
position of disulfide bonds, glycosylation sites , and secondary structure (73). In its 
physiologically active form, Epo is made up of 165 aminoacids with two disulphide 
bonds (Figure 1.6) (72) . 
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The disulfide bridges are formed by cysteines at position 7 and 161 and 29 and 33 . 
Furthermore, Epo is made up of 40% carbohydrate containing high amount of sialic 
acid (74). ,Minimal loss of sialic acid from the carbohydrate moiety results in almost 
complete loss of biological activity in vivo as measured by the ex-hypoxic mouse 
assay (75). The carbohydrate residues although not important for its physiological 
function, prevent its rapid removal from the circulation (76). 
Figure 1.6: The primary amino acid sequence of human erythropoietin. The sequence is 
folded arbitrarily for illustration. Two disulphide bonds link Cys 7 with Cys 161 
Cys 29 with Cys 33. The three N-linked glycosylation sites occur at aspartyl 
residues 24, 38 and 83. One 0-linked glycosylation site is present at Ser 126. 
160 166 
CHO 
(Adapted from Lappin TRJ & Maxwell AP. Chemistry and assays of erythropoietin . In: 




1.4.3 Sites of Production: 
Kidney: 
Soon after birth the major site of Epo production changes from the liver to the kidney. 
Several studies hav~ addressed the question as to which renal cells synthesise the 
hormone. Immunohistochemical studies with purified antiserum to recombinant human 
Epo, indicated the tubular cells as the major site of Epo production in hypoxic mouse 
kidneys (77). In situ hybridization data, however, are controversial. Koury et al (78) 
and Lacombe ·et al (79) showed Epo messenger RNA is located in the peritubular cells 
in the cbrtex and the outer renal medulla of kidneys from anaemic mice. Some of the 
radiolabelled cells in these studies had an endothelial-like morphology (78) and they 
contained factor VIII-related antigen (79). Thus peritubular capillary endothelial cells 
have been considered the most likely candidates for expressing Epo mRNA in the 
hypoxic murine kidney. In a recent study, however, in which digoxigenin-labelled 
oligonucleotide probes were employed, in situ hybridization for Epo messenger RNA, 
localized signals in the proximal tubular cells of the inner third of the renal cortex of 
hypoxic mouse kidney (80). 
Liver: 
The liver is the primary site of the foetal synth.esis of Epo (81,82), and it is also the 
• • • 
,• I 
• 
main extrarenal site of the production of blood-borne Epo in adults (83). The site of 
• . 
' • I 
production within the liver is not clear. Fried et al (84) considered the bile duct 
epithelium to be the site of the synthesis of Epo in the liver, because elevated plasma 
/ 
levels of the hormone were measured in rats with bile duct hyperplasia. 
Immunofluorescent studies located the site ofEpo production to the Kupffer cells (85) 
in extirpated fetal mouse liver. In situ hybridization showed that Epo production 
occured predominantly in centrilobular epithelial cells in the livers of transgenic and 
normal mice following the induction of anaemia (86). 
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Tissue macrophages: 
Murine myeloid and splenic macrophages in culture have been reported to contain 
erythropoietic activity (87-88) . In normal mouse marrow smears, 30% of all 
macrophages were found to be positive for Epo gene expression by hybridization 
studies (89) . On the basis of these findings, it has been argued that the paracrine 
release of Epo from macrophages maintains Epo under steady-state conditions, 
whereas the endocrine production of the hormone in the kidneys and liver is of 
importance during hypoxic stress (90). 
1.4.4 Regulation of Formation of Erythropoietin: 
Epo has its predominant effect on the committed erythroid cells defined as the colony-
forming unit erythroid (CFU-E)(91). Epo promotes their differentiation and 
development into mature red blood cells which are then released into the circulation. 
This process is under negative feedback control (Figure 1. 7) (92) . The increased 
proliferation of red blood cells results in the increased red cells mass which improves 
oxygen tran·sport and delivery, thereby alleviatin~ tissue hypoxia and switcping off Epo 
production. Hypoxia may be caused by various factors including decreased 
atmospheric oxygen tension (high altitude), anaemia, ischaernia, increased metabolic 
1
rate; respiratory disease and toxins affecting the oxygen affinity of haemoglobin. 
F'igure 1.7: Model for the regulation of erythropoiesis · (Adapted from ref 92) • 
j 
Hematopoietic Tissues 
stem cells ,.. BFU-E ,.. CFU-E ,.. Erythroid precursors 
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The stimulus for erythropoiesis appears to be oxygen deprivation in a critical re
nal 
sensor cell resulting in the initiation of a cascade of events leading to increas
ed 
synthesis and/or secretion of Epo (93,94). Possible mediators thought to be releas
ed 
during hypoxia and involved in the synthesis and or release of Epo include: adenosi
ne, 
eicosanoids, oxygen free radicals, cathecolamines and calcium. Apart from adenos
ine 
there has been no convincing evidence that any of these substances have a
ny 
pathophysiological significance. Ohigashi et al (95), using two new adenosine 
A2 
agonists, showed marked increases in Epo production by infusion of the c9mpounds
 in 
exhypoxic polycythaemic mice. The compounds also produced significant increases
 in 
mean levels of Epo in cloned Epo-producing Hep3B cell line after 18 hours incubati
on 
in 1 % 0 2. More recently, Nagashima and Karasawa (96) determined th
e effects of 
adenosine receptor agonist and antagonist on serum Epo concentration in normal a
nd 
anaemic rats. They concluded that adenosine mediates the Epo production in respon
se 
to hypoxia in the kidney. The fact that theophylline, a non-specific adenos
ine 
I 
antagonist, significantly attenuated the production of Epo in eight patients w
ith 
I i 




be: involved in the transfer of "messages" from the oxygen sensing cells · to the E
po 
producing cells in the kidney (Figure 1.8). Furthermore, this study suggested t
hat 
theophylline may be useful for the treatment of erytl\focytosis after re
nal 
transplantation (97) . 
Besides hypoxia, Epo production is most reliably stimulated by the administration
 of 
cobalt. It has long b~en appreciated that cobalt increases the red cell mass in both m
an 
(98) and experimental animals (99) . Experiments with intact animals (99), perfus
ed 
kidneys (100) and Hep3B cells (101). have shown that cobalt stimulates erythropoies
is 
by increasing the production of Epo, thus suggesting. that cobalt may be useful
 in 
studying the oxygen sensing mechanism. 
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Figure 1.8: Schematic model for the role of second messengers and hypoxia in the 
regulation of kidney production of erythropoietin. 
Epo = erythropoietin; R = receptor; Gs = G stimulatory; Ac = adenylate cyclase; 
ATP= adenosine triphosphate; cAMP = 3', 5' -adenosine cyclic monophosphate 
HYPOXIA 








(Adapted from Fisher J & Nakashima J. Erythropoietin. Contributions to Nephrology 1994). 
Epo 
The initial suggestion (102) that cobalt acted through inhibition of cellular oxidative. 
phosphorylation is not tenable since more potent inhibitors of cell respiration, such as 
cyanide, have no effect on Epo production (103). Many proteins that participate in 
. reactions with molecular oxygen do so via a haem moiety.for example haemoglobin. 
When the ferrous iron atom in the centre of the porphyrin ring of haem binds oxygen, 
the haemoglobin molecule changes its conformation from deoxy or tense (T) state to 
the oxy or relaxed (R) state (104,105). Furthermore, it has been shown that cobalt, 
can be substituted for ferrous iron in the centre of the prophyrin ring of haem. 
However, cobalt haemoglobin binds oxygen with low affinity (106), hence, the 
resulting metal-substituted porphyrins are able to bind carbon monoxide. 
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Based on these facts Goldberg et al. (101) have proposed that the oxygen sensor for 
. . 
the regulation of erythropoietin production is a haem protein that is dependent on the 
oxygen tension to which Epo producing cells are exposed (Figure 1.9). When the 
oxygen tension is sufficiently low, this haem protein is in the deoxy conformation and it 
triggers increased expression of the erythropoietin gene. Conversely, when the oxygen 
tension is sufficiently high, the haem protein is in its inactive oxy conformation and 
does not stimulate Epo production. 
When cobalt is introduced into this environment it can substitute for ferrous iron in the 
porphyrin ring. The resulting substituted haem protein is locked in the deoxy 
I 
conformation and, like the native deoxygenated iron haem protein, acts to increase Epo 
expression. Although this postulate is a very plausible explanation for the oxygen 
sensing mechanism, this haem protein has not yet been identified. 
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Figure 1.9: Proposed model for the oxygen sensor in erythropoietin-producing cells. 
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Recently Ohigashi et al (107) showed that the nitric oxide (NO) and guanosine 3 ',5' 
cyclic monophosphate ( cGMP) system played an important role in oxygen sensing and 
hypoxic regulation of Epo production. NO is now known to mediate several biological 
processes (108,109) not only in blood vessels but in several other tissues, by activating 
soluble guanylate cyclase (SGC) to generate cGlVIP. Both SGC and nitric oxide 
synthase (NOS) are haem proteins (110). Yoshioka and Fisher (111) have attempted 
to clarify the role of NO/cGlVIP 'system in hypoxic regulation of Epo production using 
the isolated perfused rat kidney . model. When arterial P02 was reduced from 100mm 
Hg (normoxaemic) to 30mm Hg (hypoxaemic) in the perfusate of the system, perfusate 
levels of Epo were significantly increased. This hypoxia induced stimulation of Epo 
I 
production was significantly decreased by a specific inhibitor of nitric oxide synthase. 
Analysis of gene expression by quantitative reverse transcription-polymerase chain 
reaction also revealed that hypoxaemic perfusion produced significant increases in Epo 
mRNA levels in the kidney, which was blocked by a specific inhibitor of NOS. Thus it 
is possible that hypoxia could induce transcription of the Epo gene via modulation of 
transcription factors . 
l 
The mouse Epo gene has a high similarity to the corresponding human gene (112), and 
1 
its has been used as a model to elucidate regulation of Epo gene transcription. Beru et 
al (113) identified two nuclear factors from the kidneys of mice which bound to the 
promoter of th,e Epo gene, specifically to the -61 to -45 region. One of these proteins 
has a MW 4 7 kDa, whereas the other is a ribonucleoprotein. When mice were made 
anaemic with a cobalt stimulus or subjected to hypoxia, binding of the 
ribonucleoprotein to the transcription site is greatly r~duced resulting in induction of 
the Epo gene. The ribonucleoprotein may therefore be a negative transcriptional 
regulator of the Epo gene. 
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Studies to identify those DNA sequences within and surrounding the Epo gene that are 
important in Epo gene expression and Epo mRNA stability are being actively pursued. 
The human hepatoma cell lines Hep3B and HepG2 have provided an appropriate 
- . I 
model for studies of this system (114). As with physiological induction of Epo 
production in the whole organism', Epo production by HepG2 and Hep3B in tissue 
culture is induced by hypoxia and cobalt but not by other stresses such as cyanide 
exposure or heat shock (115) . Transfection of these hepatoma cells, with 
enhancer/promoter constructs, has defined an oxygen regulated enhancer commencing 
approximately 120 bp 3' , to the poly A addition site of the human and mouse Epo 
I . 
genes (116-120). The active enhancer sequence lies in a region of at least 150 bp of 
striking homology between human and murine Epo gene loci . Deletional analysis of the 
murine enhancer showed that approximately 60 - 70 bp's were required for enhancer 
action when the sequence was placed 1.4 kb 5' to an a glob in reporter gene ( 118). 
Hypoxia inducible operation of this sequence was further demonstrated in a wide 
variety of mammalian cell types which are not derived from liver or kidney and which 
do not produce Epo (121 ). Further work needs to be carried out to precisely define the 
I 
sequences of the enhancer involved in hypoxic regulation of the Epo gene. 
1.4.5 The Erythropoietin Receptor: 
With the availability of biologically active, highly purified; · radiolabelled recombinant 
human erythropoietin, studies have been undertaken to better characterisJ the 
erythropoietin receptor. Because of the difficulties in purifying primary BFU-E and 
I • 
CFU-E, many of these studies have been performed on transformed murine erythroid 
cell lines, some of which are erythropoietin-dependent (122-126) and some of which 
are not (127,128). 
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Sawyer et al (129) identified two polypeptides of MW 85 and 100 kDa but V8 
protease digestion suggested that the smaller polypeptide is possibly a degradation 
product of the larger one. 
In a major advance, D' Andrea et al (130) cloned the murine Epo receptor. Two 
independent cDNA clones encoding the Epo receptor were isolated from a pXM 
expression library made from uninduced murine i (MEL) cells. The clones were 
identified by screening the transfectants for binding and for uptake of radiolabelled 
Epo, on the assumption that Epo could be internalised by receptor mediated 
endocytosis. From the cDNA sequence it may be inferred that the rriurine Epo receptor , 
is a 507 amino acid polypetides with a single membrane-spanning domain. 
The human Epo receptor was isolated from erythroleukernia cells and foetal liver, and 
its coding sequence determined (131 ). The human gene has been localized to 
chromosome 19p by in situ hybridization (132) . The predicted sequence of 508 amino 
acids of the receptor protein shows 82% homology to the murine Epo receptor 
I 
(131 , 132). Heterologous expression of the humari cDNA in COS cells yielded a 
i I 
protein of MW 66 kDa (131). The reason for the difference in molecular mass of the 
cDNA-derived Epo receptor and that described by Sawyer et al is not yet understood. 
Seeking h?mology between the Epo receptor and other receptors D' Andrea et al and 
Bazan (133,134) used sequence and structure pattern matching techniques to extract 
common features from the different receptor sequences. Homologous 
extracellularfactor-binding domains were identified in ten receptors - thbse for Epo, 
. ' 
IL-1, IL-4, IL-6, IL-7, GRH, PRL, granulocyte macrophage colony-stim~lating factor 
(GM-CSF), G-CSF and the ~ chain of the IL-2 receptor. This haemopoietin receptor 
superfarnily is characterised by an N-terrninal set of conserved cysteine residues except 
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in the case of IL-7 receptor (135) and a C-terminal collection of spaced aromatic 
residues, termed "WSXWS" box in one letter code notation, with X representing a 
non-conserved residue (135). However, many questions regarding the structure and 
function of the Epo receptor still remain to the answered, particularly how is the signal 
to proliferate and differentiate transduced when Epo binds to its receptor? Additional 
studies currently in progress are attempting to answer the question. 
1.4.6 Erythropoietin and Anaemia of Chronic Disorders: 
Several ~tudies have investigated serum Epo in inflammatory disease. The first stl1dies 
were performed using bioassays. These generally indicated that serum Epo levels were 
I 
lower than expected (136-138). The problems concerning bioassays are well known: 
the sensitivity is low, for assay methods using polycythaemic mice, and there are 
problems with the specificity of the in vitro system. Thus no conclusive evidence could 
be put forward regarding the role ofEpo in ACD. However, further studies have now 
been performed using accurate immunoassays. Most of these studies have employed 
! 
radioimmunoassays with polyclonal antisera, and most recently, recombinant standards 
I 
and 125 I - recombinant human Epo. Using such assays, normal serum levels of ~po 
, I 
were showh to be in the vicinity of 4-48 mU/ml, with different assays yielding slightly 
different, but overlapping, normal ranges (139-143). 
The availability of these accurate immunoassays, and the po.tential to intei:vene with 
recombinant human Epo, enabled investigators to survey anaemia of div_erse aetiologies 
to determine if the Epo response was appropriate. One question raised by this 
approach was that, given t~e wide range of 'normal' Epo responses, what are 
appropriate control populations with which to compare the adequacy of the Epo 
response? 
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Erslev et al (144) and Birgegard et al (145) found that Epo responses in anaemic 
patients with rheumatoid arthritis and other inflammatory arthritides appeared to be 
similar to the responses in other types of anaemia without active inflammation. On the 
other hand a study by Baer et al (146) suggested that Epo responses in patients with 
rheumatoid arthritis and anaemia, the Epo response is blunted compared to a control 
population of anaemia of other aetiologies. Hochberg et al (147) also reported that 
patients with rheumatoid arthritis had an impaired serum-immunoreactive Epo 
response to anaemia compared to a control group with iron deficiency anaemia. 
Similarly, there have been reports of blunted Epo responses for a given degree of 
anaemia in patients ~ith cancer (148), HIV infections (149), multiple myeloma (150) 
and ulcerative colitis (151) The cause for the blunted Epo response has not been fully 
elucidated. Recent experimental observations showed that certain cytokines namely 
recombinant TNFa and IL-I are capable of inhibiting Epo production by HepG2 and 
Hep3B cells in vitro (152,153). IL-I is also known to induce fever, leukocytosis, acute 
phase protein synthesis, and hypoferraemia, which are all typical features of chronic 
I 
infectious and inflammatory diseases (154,155). Recombinant IIJ-lf3 markedly 
I 
i 
suppressed colony fo~mation of erythroid progenitor cells (156) and seems to be 
! I 
identical with leukocyte endogenous mediator or leukocyte endogenous mediator 
described by Lee (32) more than a decade ago, as probably the 'final common 
pathway' th.at connects the various diseases associated with ACD. 
1.4. 7 Response of Anaemia of Chronic Disorders to Erythropoietin: 
The relative deficiency in the Epo response to ana,emia in ACD led to consideration of 
the use of Epo as treatment for this anaemia. The possibility that exogenously 
i 
administered Epo might correct anaemia in rheumatoid arthritis could not be examined 
until supplies of the hormone became available through recombinant DNA technology 
(73) . Winearls and his co-workers carried out the first clinical trials to establish the 
efficacy of Recombinant Human Erythropoietin (rHuEpo) in the reversal of anaemia 
due to chronic renal failure (157). 
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In the case of ACD, because of the blunted Epo response when compared with iron 
deficiency anaemia it was felt that administration of exogenous Epo would have no 
effect on the haematocrit (158) . Nevertheless, studies on two patients suggested that 
anaemia in rheumatoid arthritis can be corrected using rHuEPO (159). A multicentre 
study confirmed that patients with this disease showed excellent haematologic 
responses to rHuEpo without toxicity (160). 
Further studies followed with the administration of rHuEpo to patients with multiple 
myeloma (161) AIDS (162) and Crohn's disease (163). In the anaemia of AIDS, it was 
observed that patients with Epo levels of 500 U per litre or less r_esponded to moderate 
! 
doses of rHuEpo whereas those with baseline levels of more than 500 U per litre did 
not. Serum gamma interferon is increased in patients with AIDS and an inverse 
relationship has been shown with the haemoglobin level (164). Gamma interferon 
inhibits colony forming units erythroid (CFU-E) formation (165). The amount of 
rHuEpo required to overcome the inhibitory effect depends on the amount of gamma 
interferon present (166).! This suggested that cases of ACD not responsive to rHuEpo 
i 




From this literature review, it can be seen that the incidence of tuberculosis in Soutn 
Afri,ca,. like the rest of the world, is increasing rapidly especially amongst th.e coloured 
population of the Western Cape. A major contributor to the morbidity of the disease _is 
amiemia, the pathogenesis of which has not yet been elucidated. This anaemia is 
classified as anaemia of chronic disorders. ¢ytokines, like tumour necrosis factor alpha 
and interleukin-I, have been shown to play central role in both iron metabolism and 
erythropoiesis, in diseases like rheumatoid arthritis, cancer and acquired immune 
deficiency syndrome. Furthermore, in such patients there appears to be a blunted 
erythropoietin response to the anaemia when compared to a control group with iron 
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. deficiency anaemia. The cause for this has not been fully elucidated. An important 
aspect of the regulation of erythropoietin gene transcription lies in the enhancer 




ERYTHROPOIETIN AND IRON MEASUREMENTS IN 
PATIENTS WITH ACTIVE PULMONARY TUBERCULOSIS. 
2.1 Introduction 
Tuberculosis in South Africa especially in the Western Cape, is increasing at alarming 
proportions (4). It is a major cause of death (3), but for the great majority of 
: 
Mycobacterium tuberculosis infected individuals the disease is associated with great 
morbidity. A major contributory factor to. the morbidity is anaemia. The prevalence and 
severity of the anaemia associated with pulmonary tuberculosis (PTB) have been 
described (21,22) but no work as yet been carried out investigating its pathogenesis. 
The anaemia of tuberculosis is classified as anaemia of chronic disorders. In other 
disease states associated with this anaemia, namely, rheumatoid arthritis, Crohn's 
disease and cancer, a number of factors have been identified as contributing to the 
anaemia: a) decreased red cell survival, b) di,sturbances in iron metabolism and c) 
i 
blunted erythropoietin response to the anaell\ia.[With the arrival of recombinant human 




To explore the possibility that in PTB similar Epo response to anaemia occurs, the 
correlation between erythropoiesis, iron status and disease activity was prospectively 
studied. 
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2.2 Materials and Methods 
2.2.1 Patient Selection: 
I 
Forty individuals were divided into four equal groups. The first consisted of newly 
diagnosed non-pregnant anaemic patients with PTB and no dissemination or other 
associated systemic illnesses. The second, was a matching group of patients with 
:, normal haemoglobin levels. The third, were otherwise healthy people having absolute 
iron deficiency: menorrhagia in, three, gastrointestinal tract bleeding from benign 
lesions in four, and three were blood donors. The haemoglobin levels corresponded to 
those in Group I. Ten healthy volunteers made up group IV. All four groups were 
matched for age and gender. 
PTB was diagnosed according to the criteria of Escreet & Cowie (167) (Appendix 1). 
Treatment involved a standard daily drug regimen of isonicotinic acid hydrazide (INH) 
390mg, rifampicin 450mg or 600mg, streptomycin lG intramuscularly and 
' I 
pyrizinamide 1.5G. Compliance with medication was ensured by supervised 
administration of medicines by nursing staff at Brooklyn Chest Hospital and the Chapel 
Street Clinic, Cape Town. 
2,2.2 Laboratory Studies: 
All patients and healthy individuals had the following routine investigations: 
Full blood count including differential count (Technicon Hl™ auto'mated haematology 
analyser (168); vitamin B12, serum and red cell folate (Radioimmunoassay, Amersham 
International); biochemical profile (SMAC 11 AutoAnalyser, Technicon, Tarrytown, 
USA); C-reactive protein (CRP) quantitatively by immunodiffusion (169); serum iron, 
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total iron binding capacity and red cell and serum ferritin were determined according 
to standard methods (170,171). These investigations were carried out by the 
Haematology and Chemical Pathology laboratories of Groote Schuur Hospital, Cape 
Town. 
Serum erythropoietin levels were determined by an established radioimmunoassay 
{Incstar EPO-TRAC RIA, Minnesota, USA). This was carried out at the 
Pharmacology Department of the University of Cape Town, Medical School. 
All measurements, in patients, were carried out before commencing treatment and in 
the case of the anaemic PTB patients repeated every four weeks for a period of three 
months. Full haematological details including serum biochemistry of patients in each 
group appear in Appendix 2. 
2.2.3 Ethical Cobsiderations: 
1. Informed consent: 
Written or oral (in the case of patients that could not write) informed consent was 
' secured from each patient before inclusion into the study. 
Patients were fully informed in non-technical language of the nature of the drugs, the 1 
adverse events, objective and design of the study including the various blood tests, 
and their freedom to withdraw at any stage for any reason. 
2. Ethics Committee Approval: 
The protocol, subject information and consent form were submitted to Ethical Review 
Committee of the University of Cape Town Medical School. The study was only 
initiated after approval by the Committee. 
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3. Confidentiality: 
.confidentiality of all subjects' identity was maintained by assigning a number to 
identify the subject in each Group. Only the subject's number was used to identify the 
subject for the duration of the study. The subject number will be used in the reporting 
.of the data for the purpose of this thesis. 
2.2.4 Statisti~al Analysis: 
" 
Data are rerorted as mean±SEM. The Mann-Whitney U-Test was used for the 
comparison of Hb, Epo and CRP levels between the various groups of patients and 
healthy volunteers. The analysis of variance (ANOVA) was used for '.the comparison of 
Hb, CRP, serum iron and ferritin before and at the various stages of anti-tuberculous 
therapy in the anaemic PTB group. Wherever the variations were not homogeneous 
log transformations were performed. Data were analysed using the STATPAK 
statistical package. Regression analysis was done us~ng haemoglobin as independent 
• I 
variable and erythropoietin as dependent variable. (Statistical methods by Srledecor 
GW & Cochran WG, Iowa State University Press, 1980). 
2.3 RESULTS 
Patients in Group I had a mild anaemia with a mean haemoglobin concentration of 
94±4 g/L and MCV of 82±3 .6. Despite a mean seruin ferritin of 638±137 ug/L the 
mean serum iron was only 5.6±0.4 umol/L and the TIBC 44±1.1% (Table 2.1). 
Patients with iron deficiency anaemia (Group II) had the same mean haemoglobin 
concentration, however the mean serum ferritin was only 9±0.9 ug/L with a mean 
serum iron of 4.1±0.4 umol/L and mean transferrin saturation of74±1.9% (Table 2.1). 
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It must be noted that the mean serum vitamin B 12, serum folate and red cell folate 
were well within the normal ranges (see Appendix 2) in all four groups (Table 2.1). 
For the same degree of anaemia, there was a significantly lower serum Epo level in 
patients in Group I than in Group III (p<O.01, Figure 2.1) 
I 
Table 2.1: Relevant personal and haematological values (mean ± SEM) of patients 
and healthy volunteers. 
GROUP I GROUP II GROUPID GROUP IV 
Age (yrs) 34±3 38±3 30±3 31±3 
Gender 7M:3F 7M:3F 5M:5F 5M:5F 
Hb (.g/L) 94±4 134±14 94±5 140±6 
MCV (fl) 82±3.6 91±2.2 75±2.3 90±1 .6 
MCH(pg) 26±1.3 31±0.8 23±1.4 31±0.7 
CRP (mg%) 7.8±0.6 3.3±0.3 - -
Iron (µmol/L 5.6±0.4 14±1.5 4.1±0.4 15±0.8 
TIBC 44±1.1 51±0.6 74±1.9 57±1.0 
Saturation (%) 12±0.4 27±2.5 6.1±0.6 26±1.5 
Sernm Ferritin (µg/L) 638±137 202±42 9±0.9 66±8 I I 
Red Cell .f erritin (fg/cell) 0.02±0.002 0.02±0.001 0.01±0.002 0.02±0.0011 
Vit B 12 (pg/ml) 64o±n8 740±101 437±20 512±33 i 
sernm Folate (ng/ml) 3.5±0.7 3.3±0.2 5.2±0.4 5.3±0.3 l 
Red Cell Folate (ng/ml) 469±42 384±48 264±44 483±34 
Serum Epo (mU/ml) 54±11 21±3 142±41 23±0.8 
Group I : Anaemic PTB patients, Group II: Non-Anaemic PTB patients, Group III: Iron 
deficiency anaemia patients, Group IV: Healthy Volunteers. 
Prior to the initiation of therapy, patients with PTB but not anaemic (Group II) had a 
mean CRP level of 3 .3±0.3 mg%. This was significantly lower (p < 0.002) than the 






















Figure 2.1: Comparison of Hb and Epo serum levels (mean ±SEM) in patients and 
healthy volunteers. For the same degree of anaemia, patients in group I had a 
















Group I Group II 
Figure 2.2. Comparison of CRP between anaemic (Group I) and non-anaemic (Group 
II) PTB patients before therapy . * Indicates the mean value as shown in Table 2.1. 
There was a significantly higher CRP level in the Group I patients compared to the 
Group II (p<0.002). 
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In the Group I patients, effective anti-tuberculous therapy; resulted in a significant rise 
(p < 0.025) in mean haemoglobin concentration to 131±4 g/L at 3 months. 
Furthermore, anti-microbial therapy resulted in a significant fall (p < 0.001) in the CRP 
level to 2.2±0.6 mg% at 3 months). Concurrently there was a significant rise in serum 
iron (p < 0.0001) but although the fall in serum ferritin did not reach significance levels 
there was downward trend. With the rise in haemeglobin there was a significant fall in 
Epo serum levels (p < 0.025). All these changes are illustrated in Fig 2.3.(Table 2.2). 
Table 2.2: Effect of anti-tuberculous therapy on Hb, Epo, CRP and iron parameters of 
the anaemic PTB patients (Group I). Data shown as mean± SEM. 
TIME (Months) 
0 1 2 3 
Hb (g/L) 94±4 108±4 117±4 131±4 
Epo (mU/ml) 54±11 29±2 22±1.7 20±2 
CRP (mg%) 7.8±0.6 5.5±0.8 3.9±0.7 2.2±0.6 
serum Iron (umol/L) 5.6±0.4 10.1±0.7 12.4±1.3 16.1±1.7 
TIBC 44±0.4 49±0.3 I 50±0.3 51±0.3 
Saturation (%) 12±0.4 20±0.5 f 25±0.4 33±0.3 
serum Ferritin (ug/L) 638±137 594±138 i 458±126 423±131 
Regression analyses of the relationship between Epo and Hb in the groups I and III 
patients , are shown in (Figure 2.4 a,b) . There was significant correlation between Hb 
and Epo in the two groups. In the Group I patients the correlation coefficient r was 
0.60 with a significance level p < 0.03 . In the Group III patients r was 0.65 with p < 0. 
0.02. However the slopes and intercepts of the two lines were different. iln the Group I 
; : 
patients the slope was -1.65 with an intercept at 210.3 (mU/ml) compared to the 
Group III patients with a slope of -5 .92 and intercept at 700.8 (mU/ml). Thus it 
appears that the Epo response to anaemia is blunted in the Group I patients, however 
the normal physiological response to anaemia is still oper;itional. 
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Figure 2.3c 
Figure 2.3abc: Effect of anti-tuberculous therapy on Hb, CRP, sernm iron, ferritin and Epo in 
anaemic PTB patients. Data were obtained as described in Materials and Methods. With therapy 
there was a significant fall in the CRP levels and this resulted in significant rise in Hb and serum 
iron. With the rise in Hb there was a significant fall in the Epo serum level. The significance level 
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Figure 2.4a. Regression analysis of anaemic PTB patients (drou·p I). Epo and Hb levels 
were determined as described in Materials and Methods. The slope was -1.65 the 
intercept was 210.3 and the correlation coeffeicient r=0.60 with a significant level of 
· p<0.03. The curved lines represent 95% confidence intervals. 
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Figure 2.4b Regression analysis of anaemic Iron deficiency patients (Group III). Epo and Hb levels 
were determined as described in Materials and Methods. The slope was -5.92, the intercept was 
700.8 and the correlation coefficient r=0.65 with a significance level of p<0.022. · 
_The curved lines represent 95% confidence intervals. 
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2.4 DISCUSSION 
The diagn~stic feature of anaemia of chronic disorders (ACD) is hypoferraemia with 
low serum transferrin or low serum total iron binding capacity in the setting of 
adequate iron stores (23) . The mild anaemia of the patients with active PTB typifies 
this anaemia in that the serum iron was reduced with adequate body iron stores as 
shown by the serum and red cell ferritin with the former being a less reliable marker 
since it behaves as an acute phase reactant (171). 
The development of anaemia during chronic disease is not well understood. Two 
possible explanations can account for the ; observations: i) interference in iron 
metabolism and ii) decreased levels of Epo. 
Cartwright ( 40) postulated that the anaemia of chronic disease may be due to a block 
of release of iron from the RES . Although animal models of ACD supported this 
I 
theory ( 41 ), no evidence of a blocked RES iron releasd could be demonstrated in 
patients with rheumatoid arthritis (42) and pulmonary tuberculosis (21). In the latter 
study, Baynes et al argued that the anaemia of PTB could not be due to iron deficient 
erythropoiesis as the percentage saturation of iron between anaemic and . non-anaemic 
individuals were the same (that is 31 %). It must be pointed out that all patients had' 
been on anti-tuberculous therapy for at least one month prior to any measurements 
being made. 
In this study, the mean percentage saturation of iron in the anaemic PTB patients 
(Group I) was only 12 % before commencement of therapy. Within one month of anti-
tuberculous therapy, there was a rapid rise in serum iron with a percentage saturation 
of 20 % (Table 2.2). This in agreement with the observations of Morris et al (22). 
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Thus it appears that prior to commencement of anti-tuberculous therapy, iron deficient 
erythropoiesis may play a role in the pathogenesis of anaemia of PTB. 
The impaired mobilisation of iron in patients with ACD may be the result of cytokines 
released during the inflammatory/infective process. Moldawer et al (61) showed that 
injection of recombinant TNFa in rodents resulted in hypoferraemic anaemia 
associafed with impaired RES iron release and incorpora,tion into erythrocytes. Denz et 
al (59) showed that the degree of activation of macroph.ages - as measured by the 
serum neopterin concentration - in patients with malignancy resulted in the 
development of anaemia by a shift of iron toward storage sites suggesting a role of 
immune activation in altered iron metabolism. Rogers et al (60) reported that 
interleukin 1 (IL-1) increased translation of ferritin rnRNA and have suggested that this 
additional ferritin might act as a trap for iron that might otherwise be available for 
erythropoiesis. 
In this study the significantly loweir CRP level in the non-anaemic PTB group 
compared to those with active PTB and anaemia, argues for the degree of 
inflammation being causally related to the anaemia. With anti-tuberculous therapy there 
I • 
was a significant rise in serum iron and downward trend of serum ferritin . These 
findings are compatible with the above studies i~ that anti-tuberculous therapy may 
. i . ! 
have resulted in a decrease in circulating inflammatory cytokines and mobilisation of 
iron from storage sites and improvement in anaemia. 
Typically there is an inverse relationship between serum Epo levels and haemoglobin: 
as the haemoglobin decreases, the Epo level rises (144). The physiological response to 
anaemia is clearly shown in this study in that there was a significant negative 
correlation between serum Epo levels and haemoglobin in both iron deficiency and 
anaemic PTB patients. 
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However the slopes and intercepts of the regression analyses of the two parameters 
were clearly different between the two groups. In the anaemic PTB group the slope 
and intercept were less than half that of the iron deficiency group. It must be 
remembered that both groups had similar degrees of anaemia, thus the physiological 
response in the anaemic PTB group although operational is attenuatell 7'hese findings 
are consistent with those of Baer et al (146) who showed that in anaemic r~eumatoid 
arthritis patients there was an inverse relationship between haemoglobin and Epo 
levels;: however, for any given anaemic individual with rheu.matoid arthritis the Epo · 
level was lower than that found in equally anaemic individual with iron deficiency. The 
findings of a blunted Epo response to anaemia were also shown by Hochberg et al 
( 14 7) and Boyd and Lappin (172) in the case of rheumatoid arthritis. Similar results 
have been reported in patients with cancer (148), HIV infections (149), multiple 
myeloma ( 146) and ulceratice colitis (151 ). 
I 
I 
The cause for the attenuated Epo response has not been fully elucidated. Recent 
• I 
experimental observations ' showed that certain cytokines namely recombi~ant TNFa 
and IL-1 are capable of inhibiting Epo production by the hepatoma cell lines HepG2 
and Hep3B in vitro (152,153); in vitro monocyte secretion of IL-1~ was associated 
with severity of anaemia in patients with inflammatory bowel disease (151 ) . 
' 
The relative deficiency in the Epo response to anaemia in ACD led to consideration of 
the use of Epo as treatment for this anaemia. A multi centre study showed that patients 
with rheumatoid arthritis had 'excellent haematologic responses to recombinant human 
erythropoietin (rHuEpo) without toxicity (160). Further studies followed with the 
administration of rHuEpo to patients with multiple myeloma ( 161 ), AIDS (162) and 
Crohn' s disease (163). It appears that administration of pharmacological doses of Epo 
is able to overcome the inhibitory effects of inflammatory cytokines on erythropoiesis. 
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In this study as in other examples of ACD impairment of iron metabolism and 
erythropoiesis are each present, but several reasons exist for believing that the latter is 
more important: i) rHuEpo can correct ACD but cannot correct the anaemia of iron 
deficiency; (ii) iron ingestion, which increases the serum ferritin levels, has no effect on 
the anaemia of rheumatoid arthritis, but Epo n9rmalises the haematocrit; (iii) serum 
transferrin receptor levels are elevated in patients with iron deficiency, but are 
generally not elevated in patients with ACD. 
In conclusion, it appears that there are two contributory factors to the anaemia of 
active PTB, namely, a disturbance in iron metabolism and a blunted erythropoietin 
response to the anaemia. The marked decrease in the inflanunatory marker CRP with 
anti-tuberculous therapy, and the resultant rise in haemoglobin levels and serum iron 
leads one to believe that inflammatory cytokines may have been responsible for the 
haematological changes seen with this chronic disease. The effect of cytokines on 
: 
I 





MODULATION OF ERYTHROPOIETIN PRODUCTION BY 
· TUMOUR NECROSIS FACTOR ALPHA: IN VITRO STUDIES 
AND ITS CLINICAL IMPLICATIONS 
3.1 Introduction 
The production of erythropoietin is stimulated in the presence of hypoxia (91 ,92). In 
anaemic patients without renal disease an inverse relationship exists between the seru\n 
erythropoietin level and the haemoglobin concentration of the blood (144). This 
physiological response ofEpo to anaemia occurs in patients with active PTB, however 
the response is attenuated when compared to patients with pure iro~ deficiency 
anaemia (173).This is in agreement with clinical studies on other examples of ACD 
(146-150). Hence it has been proposed that as yet unidentified factors may influence 
the production of erythropofotin independently of hypoxia (174) . 
Mycobacterial lipoarabinomannan is a potent trigger of tumour necrosis factor alpha 
(TNFa.) release from monocyte-macrophages (175). TNFa. production in the 
granulomata is an essential component of the immune response to mycobacterial 1 
infections (15). The peripheral blood diononuclear cells (PBMC) from these patients 
are known to release large quantities of TNFa. in vitro (176). The fever, weight loss 
and tissue injury that characterise advanced tuberculosis may be attributable in part to 
TNFa. (17). TNFa. also exerts an inhibitory effect on. haematopoiesis, both in vitro 
' (177) and in vivo ( 61 ). Recently it has been shown that recombinant TNFa. can inhibit 
the production of Epo by the human hepatocellular lines, HepG2 and Hep3B in vitro 
(152,153). 
Trus study was undertaken to investigate whether TNFa. produced by the PBMC of 
patients with active pulmonary tuberculosis is capable of inhibiting the production of 
erythropoietin by HepG2 cells in vitro and whether the inhibition, if any, can be 
reversed by specific anti-TNFa. antibodies. 
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3.2 Materials and Methods 
3.2.1 Patients: 
Blood mononuclear cells were recovered form a total of 15 patients: Group I (n=5) 
anaemic PTB patients, Group II (n=5) non-anaemic PTB patients and Group III (n=5) 
iron deficiency anaemia patients. The patients were matched for age and gender. 
3.2.2 Monocyte Cultures: 
J:Ieparinized blood samples from PTB patients and iron deficient. controls were diluted 
(vol/vol) in calcium-free Hanks' buffered saline sol~tion (HBSS), supplemented with 
0.08% EDTA. The peripheral blood mononuclear cells (PBMC) were isolated by 
layering the samples over Fi coll Hypaque density gradient and centrifuged at 1000 · g 
for 15 minutes. In order to purify the PBMC, the adherent cells were resuspended in 
the same medium diluted 1/9 (vol/vol) in calcium-free HBSS and centrifuged (100 g 
for IO minutes) twice to remove any platelets. Thereafter, the PBMC were 
! 
I 
resuspended in culture medium made up with RPMI ~ghveld Biologicals, 
Johannesburg, SA) buffered with HEPES to pH 7.4 and supplem~nted with I% non-, 
I 
heat inactivated foetal calf serum (FCS) (Highveld Biologicals, Johannesburg, SA), 
1 OOU/ml penicillin, I 00 µg/ml streptomycin and 2mM L-glutamine. The cells were 
counted after staining with acridine orange and adjusted to a concentration of I 06 
cells/ml. 100µ1 volumes of this suspension were added to 96-well rnicroplates (Linbro 
Brand, Flow Laboratories, Inc., McLean, Virginia, USA). The total volume of each 
well was adjusted to 200~tl with complete medium. The cells were incubated with 5% 
. I 
CO2 and 20%02 for 48 hours without stimulation. The monocyte supernatant fraction 
(SNF) from patients and control were removed and stored at -70°C until assayed for 
TNFa.. 
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3.2.3 Tumour Necrosis Factor alpha assay: 
TNFa released from unstimulated PBMC was assayed by a immunoradiometric assay: 
SNF (25µ1) from patients and iron deficient controls were incubated overnight with 
125 1-labelled anti-TNFa monoclonal antibody in tubes coated with monoclonal 
antibody directed against different epitopes of TNFa (IRMA, Amersham, 
Buckingham, UK). After washing, the remaining radioactivity bound to the tube was 
counted in a gamma counter. 
3.2.4 HepG2 cell cultures: 
HepG2 cells that had been evaluated and standardised in culture (Department of 
Medical Biochemistry, Medical ~chool, University of Cape Town, obtained through 
American Type Culture Collection) were plated on 24 well polystyrol dishes (Linbro 
Brand, Flow Laboratories, Inc., Mclean, Virginia, USA) and cultured in modified 
Eagles' medium (MEM) with 10% (non-heat inactivated) FCS (Highveld Biologicals, 
South Africa and sodium bicarbonate without antibiotics. The cells were incubated at 
37°C in humidified air, with 5%C02 until 75% confluence was obtained. 
The media were then removed and the various dilutions (in duplicate) of monocyte 
SNF from patients and controls were added to the cells.· The HepG2 cells were 
incubated for a further 24 hours, after which th~ SNFs were removed a~d stored at -
20° C until analysis of the Epo concentration by radioimmunoassay (Incstar EPO-
TRAC RIA, Minnesota, USA). 
The same experiments were conducted with the 
1
addition of a 1 :800 dilution of specific 
polyclonal goat lgG-(H34) and 1:200 dilution of specific monoclonal lgG-(101-4) 
TNFa antibodies (National Biological Standards Board, Hertfordshire, UK).to the 
monocyte SNF of the anaemic PTB group. 
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3.2.5 Protein Estimation: 
In order to standardise for the number of HepG2 cells in each well, cellular protein 
estimation was done. The cells were washed with phosphate-buffered saline and lysed 
with SDS-NaOH (0.5% sodium dodecyl sulphate in O. lM sodium hydroxide). Total 
cellular protein was determined by the automated Bio-Rad dye binding microassay 
system as described by Bradford (178) using bovine serum albumin as a standard. 
Samples were diluted 50-fold prior to assay in order to minimise any interference by 
SDS-NaOH. Epo levels were then expressed as mU/mg protein. 
3.2.6 SL~tistical Analysis: 
Analysis of variance (ANOV A) was used for companson of TNFa produced by 
monocytes and for the levels of Epo produced by HepG2 cells in the presence of 
monocyte SNF from PTB patients and iron deficient controls. The results are reported 
as mean ± SEM. 
3.3RESULTS 
Adherent PBMC frorri anaemic PTB patients produced significantly higher (p < 0.001) 
TNF (770±173 pg/ml) than monocytes derived from the non-anaemic PTB patients) 
( 431±90 pg/ml). The level of this cytokine was signific<;1ntly higher (p < 0.005) in the 
monocyte SNF of the Group II patients compared to the iron deficient controls (Group 
III) (98±17 pg/ml) (Figure 3.1 A) The production of Epo by HepG2 cells were 
markedly inhibited in the presence of monocyte SNF form patients of Group I 
. I 
compared to both Groups II and III (p < 0.001) (Figure 3. IB). The results shown are 
duplicate experiments performed on five individuals in each of the three groups. 
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Figure 3.1: A Production of TNFa. by PBMC obtained from untreated anaemic PTB patients (I), 
non-anaemic (II) and iron deficient controls (III) (**p<0.001 comparing groups I and III, 
*p<0.005 comparing groups II and III). B Also shown are the effects on Epo production by HepG2 
cells in the presence of monocyte SNF from the same three groups. Data were obatained as 
described in Materials and Methods. The significantly higher levels of TNFa. produced by tl1e 
PBMC of the group I patients resulted in a marked inhibition ofEpo production by HepG2 cells 
( +p<0.001 comparing groups I and III). 
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The effects of monoclonal and polyclonal anti-TNFa. antibodies on Epo production by 
HepG2 cells in the presence of various dilutions of monocyte SNF were examined in 
the Group I patients (Figure 3 .2). The addition of increasing concentrations of 
monocyte SNF resulted in a progressive reduction of Epo produced by the HepG2 
cells. In the presence of optimal saturating concentrations of anti-TNFa. antibodies the 
release of Epo was elevated. The falloff reflects the use of fixed dose antibodies, with 
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Figure 3.2 TI1e effect of specific monoclonal antibody (mAB) or polyclonal antibody (pAb) on Epo production by 
HepG2 cells in the presence of increasing concentrations of monocyte SNF from anaemic PTB patients. Data 
mean±SEM represent measurements of Epo production after addition of monocyte SNF from 5 anaemic PTB 
patients at each dose in the presence and absence of specific anti TNFa antibodies. With increasing doses of 
SNF there was a marked fall in Epo production by HepG2 cells. This was reversed in the presence of the specific 
anti-TNFa antibodies. (p < 0.001 comparing Epo production in the presence and absence of specific anti-TNF 
antibodies). 
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3.4 DISCUSSION 
The anaemia associated with PTB appears to be explicable, at least in part, by 
reference to inappropriate plasma Epo levels, causally linked to the inflammatory 
process that leads fo the release of a number of inhibitory cytokines. 
• I 
This study showed that in vitro production of TNFa by PBMC purified from anaemic 
PTB patients was significantly greater than in the non-anaemic PTB group and iron 
deficient controls. Furthermore, monocyte SNF from the anaemic PTB group inhibited 
the production of Epo by Hep G2:, cells in vitro. The suppressed release of the hormone 
was more pronounced than in anaemic PTB patients than those with, iron deficiency, in 
keeping with the higher levels of TNFa in the anaemic PTB patients. Although the 
levels of TNFa in the non-anaemic PTB group were greater than in iron-deficient . 
controls, no observed suppressive effect on Epo production by HepG2 cells was 
observed under the experimental conditions studied. It appears, therefore, that a 
critical level of cytokine or synergistic responses may be necessary in order to block 
the increased requirement for Epo synthesis, thus contributing to the anaemia. 
I ' 
Faquin et al (152) reported that recombinant IL-1, TNFa and TGFB inhibited the 
production of Epo from the hepatoma cell line Hep3B. This effect appeared to occur at 
the level of Epo mRNA. Jelkmann and co-workers (153) using HepG2 cell line, 
reported simi.lar results for IL-1 and TNFa, but noted no inhibition with TGFB . In 
addition they reported that IL-1 B inhibited Epo iproduction by isolated perfused rat 
kidney. In a recent study, increased levels of IL-1.B was correlated with the severity of 
the anaemia in patients with inflammatory bowel disease (163). However in this study, 
the effect of the increased level of cytokine on Epo production in these patients were 
not investigated. 
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In this study, abrogation of the suppression by monocyte SNF by both poly-and 
monoclonal anti-TNFa antibodies implicates TNFa produced from activated PBMC, 
in impairing Epo release in vitro. An effect of this on erythropoiesis may explain the 
impaired response to anaemia in patients with PTB or other chronic inflammatory 
I 
conditions. 
In · a recent study (179), we showed that addition of monocyte . supematants from 
patients with chronic renal failure, resulted in a sharp drop in Epo production by 
HepG2 cells in :vitro. There was however no direct correlation between increased 
levels of TNFa, IL-la and IL-1~ and the degree of suppression. Furthermore, 
inhibtion of these cytokines by specific monoclonal antibodies did not block the 
inhibition of Epo release by HepG2 cells. 
The results of this study, demonstrate that monocytes from patients with chronic renal 
failure produce factors that inhibit Epo production by HepG2 cells in vitro. This 
observation implies that a further mechanism, in addition to reduction in renal mass, 
inhibits Epo secretipn and may also contribute to the pathogenesis of the anaemia of 
. I 
1
chronic renal failure . However, unlike tuberculosis patie~ts, the factors responsible for 
this inhibition is not the cytokine TNFa. 
TNFa has been shown to exert an inhibitory effect on haematopoesis, both in vitro 
. . ' 
(177) and in vivo (61). This effect is probably mediated by nitric oxide (NO), whose 
synthesis has recently been shown to be stimulated by both IFNy and TNFa. (180) . 
When normal bone marrow or CD34+ cells were exposed to NO, apoptosis of bone 
marrow progenitors took place. Inducible nitric oxide synthase (NOS) mRNA w~s 
found in bone marrow after stimulation with IFNy and TNFa. Presence of an NOS 
inhibitor partially reversed the effect of TNFa. 
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Furthermore, NO and 3 ', 5' cyclic monophosphate ( cGMP) system has been shown to 
play an important role in the oxygen sensing and hypoxic regulation of Epo production 
(ll l). Using the isolated perfused rat kidney model it was shown that when arterial 
P02 was reduced from IOOmrri Hg (normoxaemic) to 30mmHg (hypoxaemic) in the 
• I 
perfusate of the system, perfusate levels of Epo were significantly increased. This 
hypoxia induced' increase in Epo production was significantly decreased by a specific 
inhibitor of NOS. 
Thus, in order to understand the complex mechanisms by which TNFa and NO may 
exert their effects on Epo production, it is essential to study the mechanism of O?(Ygen 
sensing and expression of the Epo gene. This will _be elucidated in Chapter 4. 
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CHAPTER4 
OXYGEN SENSING AND ERYTHROPOIETIN GENE 
EXPRESSION 
4.1 Introduction 
Erythropoietin (Epo) plays a central role m the feedback regulation of 
- erythropoiesis in response to anaemia and reduced blood oxygenation (168) . . 
However, the Epo response to anaemia may be blunted in chronic disease like_ 
for example rheumatoid arthritis (146) inflammatory bowel disease (163) and 
pulmonary tuberculosis (173). :,This may be the result of the presence of TNFa 
which inhibits the release ofEpo in vitro (152,153,173). In order to understand 
the mechanism (s) by which this modulation in Epo production occurs, it is 
essential to study the oxygen sensing mechanism and expression of the Epo 
gene. 
The human hepatoma cell lines Hep3B and HepG2 have provided an appropriate 
model for the study of oxygen regulated Epo gene expression (114) . As with the 
physiological induction of Epq production in the whole organism, Epo 
production by these cells is induced by hypoxia or cobaltous ion, but not by 
. other stresses such as cyanide or heat shock (115). Transfection studies in these 
hepatoma cells have defined an oxygen regulated enhancer commencing 
apprnximately 120 bp 3' .to the poly A addition site of the human and mouse 
Epo genes (116-120) (Figure 4.1). 
The active enhancer sequence lies in a region of at least l 50bp of striking 
homology between human and murine Epo gene at the 3' end of the gene. 
Deletion analysis of the murine enhancer showed that approximately 60-70bp 
were required for enhancer action when the sequence was placed 1.4 kb 5' to an 
a1globin reporter gene (117). Hypoxia inducible operation of this sequence was 
further demonstrated in a wide variety of mammalian cell types which are not 
derived from kidney or liver and which do not produce Epo (121). 
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poly A 
Mouse CTGGCAACAG CTGAAATCAC CAACCAGACT CCTGGCTTGT CTCTCTTCAT 
Human TIGACAAGAA CTGAAACCAC CAATATGACT CTIGGCTTTI CTGTTTTC - -
Mouse GACTGTACAC ACCACACAAC TCTCCTAGCT GTACCTCACC CCATCTGGTC 
Human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
l Apal 
Mouse GCAAGGCATC AGATCTGGGA AACCAGAGGT CGAGGGGGTT GGGCCCTACG 
Human - - - - - - - - -C AGGTCCGGGAAATGAGGGGT CGAGGGGGCT GGGCCCTACG 
11 21 31 41 51 
Mouse TGCTGCCTCG CATGGCCCGG CTGACCTCTT GACCCCTCTG GGCTTGAGGC 
Human TGCTGTCTCA CACAGCCTGT CTGACCTCTC GACCTACCG G CCT AGGC 
61 71 81 91 101 
Mouse CACAATACCT GCCCACGCTA GTCAATAAGC AGGCTCCATT GAAGGCTGTC 
Human CACAAGCTCT GCCTACGCTG GTCAATAAGG TGTCTCCATT CAAGGCCTCA 
111 Pvull 
' Mouse TCTCAGTGGG CAGCT 
Human CCGCAG 
Figure 4.1: Comparison of the human and murine DNA sequence at the 3' end of the 
Epo gene. In each case the active enhancer sequence is located approximately 120 bp 3' 
to the poly A addition site (underlined) . Sequence conservation is approximately 85% 
within the functionally defined enhancer, although the best alignment is achieved by 
making gaps as shown in the human sequence. The murine sequence in this region has 
been numbered from Apa! site to facilitate description of constructs containing part of 
this sequence. The dashed line in the human sequence indicates the area where no 
significant homology exists. 
In order to further characterise the sequences of the Epo enchancer involved in 
oxygen sensing and gene regulation detailed studies of the mouse Epo enhancer 
were carried out. This involved transfection experiments of deleted, mutated and 
re-iterated . sequences plus DNAse 1 protection analysis, to define the 
subsequences within the enhancer. However, since the operation of an enhaAcer 
in differ.ent cell types may result from different DNA protein interactions 
' i 
(182,18~), the experiments were carried out in different cell types: HepG2 cells, 
which produce Epo and support regulated operation of the mouse Epo 3' 
enhancer and the Chinese hamster lung fibroblastoid line, a23, which support 
regulated enhancer function but do not produce Epo. 
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4.2 Materials and Methods 
4.2.1 Cell lines and culture conditions: 
HepG2 cells were grown in minimal essential medium with Earle's salts 
- . I 
supplemented ~ith 10% foetal calf serum, glutamine (2mM), penicillin (50 iu/ml) 
and streptomycin sulphate (50 ug/ml). a23 cells, were grown in the same 
medium with the addition of sodium pyruvate (lmM). 
4.2.2 Plasmid Constructs: 
. . . 
After -growth in E . coli, plasmid DNA was prepared by alkaline lysis (184) an,d 
purified on a caesium chloride gradient Constructs containing deletions of the 
mouse Epo enhancer linked to a 2570 bp Bg/11 - PpuMI fragment containing the 
intact human a 1 globin gene with 1.4kb of 5' flanking sequence, in either 
orientation, into the Notl site of pBluescript SK.II (Stratagene Ltd., Cambridge) 
were made with appropriate linkers (pBSa-) (118) . To assess the effects of 
distance of the enhancer sequence from the promoter, the 2570 bp a1 globin 
fragment was exchanged for an otherwise iden~ical fragment which was deleted 
to position - 124 in the a1 globin 5' flanking sequence (pBS~a1). The enhancer 
nucleotides present in these plasmids were designated by numbers related to the 
first nucleotide of the Apa I site at the 5' end of the enhancer (Figure 4.2). 
l 25 
AGATCTGGGAAACCAGAGGTGGAGGGGGTfGGGCCCTACGTGCTGCCTCGCATGGCCCGGC 





Figure 4.2: DNA sequence of the enhancer. Nucleotides are numbered from the first base of 
the Apa I site. Nucleotides 1-48 underwent 4 base pair mutations where the purines were 
substitutes for their non-complimentary pyrimidines and vice-versa. 
Consecutive four base pair mutations of the Epo enhancer, in which purines 
were substituted for their non-complimentary pyrimidine and vice versa, were 
made using the pALTER based Altered Sites™ in vitro mutagenesis system as 
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directed by the manufacturers (Promega Ltd., Southhampton). For these 
constructs a 460 bp sequence containing the mouse Epo enhancer was ligated 
into pAL TER. Mutagenic oligonucleotides contained the four mutated 
nucleotides flanked by fourteen complementary nucleotides on each side. After 
retrieval of the mutant plasmid and confirmation of mutation by dideoxy 
s~quencing, a 153 bp Bg/II - F vuII fragment containing the mutated Epo 
enhancer region, was subcloned into polylinker sites in pBluescript SKII which 
. contained the 2570 bp a 1 globin fragment described above (pBSa-) . A siµular 
plasmid containing the unmutated 153bp BglII- PvuII fragment from the Epo 
enhancer locus was made to enable direct comparison of function between wild 
type and mutated enhancer sequences. 
Further subsequences from within the Epo enhancer were derived either by PCR 
amplification or by annealing synthesised oligonucleotides. Generation of 
concatamers and recombination of subsequences was facilitated by using 
! 
oligohucleotides in which compatible overhanging ends could be generated from 
' I 
Xbali and Spel restriction enzymes sites. These sequences were inserted adjacent 
j I 
to the SV40 promotor in pSVGH. pSVGH contained a 198 bp NsiI-HindIII 
fragment containing the SV 40 early pro motor sequence linked to human growth 
hormone (BamHI-NsiI fragment) in pGEM7 (Promega, Southampton). Plasmids 
containing no erythropoietin sequence (pSVGH) or . the 168 bp KpnI-NsiI 
fragment containing the SV 40 enhancer instead of Epo sequence (pSVeSVGH) 
were used as controls. 
A plasmid containing 290bp of the promotor of the mouse ferritin heavy chain 
subunit gene fused to the human growth hormone gene (pFGH) was used to 
control for transfection efficiency in experiments where the test plasmid 
contained the a globin reporter gene. In experiments where the test plasmid 
contained the growth hormone reporter gene, the a globin containing plasmid 
pBSa- was used to control for transfection efficiency. 
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4.2.3 Transient Transf ection Experiments: 
Cells were transfected by electroporation (185) usmg ImF capacitor array 
charged at 375V for HepG2 cells and 400V for a23 cells. For each transfection, 
approximately 10 7 cells were mixed with control and test plasmid DNA in 1 ml 1 
ofRPMI 1640. a 1 globin plasmids were used at 50µg/ml, pSVGH plasmids were 
used at 10 µg/ml . After transfection the cell suspension was divided into two 
aliquots for parallel 16 hr normoxic and hypoxic incubations. Normoxic 
incubations contained humidified air with 5% CO2. Hypoxic incubation, 
commencing 1 hr after electroporation was in 1 % 02 with 5% CO2 and 94% N2 
in a Napco 7100 ihcubator. 
4.2.4 RNA Analysis: 
RNA was prepared usmg acid/guanidinium thiocyanate/phenol/chloroform 
extraction method (RNAzol B, Biogenesis Ltd., Bournemouth). Extracted RNA 
was assayed using RNAse protection assay. 32P labelled riboprobes were 
produced using SP6 RNA polymerase (186). The growth hormone riboprobe, 
crossed the boundaries of exon 3 and protected the entire ·111 nucleotide 
sequence of that exon. The a 1 globin riboprobe crossed the cap site of the gene; 
different probes which protected either 97 or 132 nucleotides of exon 1, were 
• I • 
used when the a1 globin reporter gene was used as th~ test plasmid, or the 
control plasmid, respectively. 
In all assays, 3-20 µg of total RNA was subjected to double hybridisation with 
I • 
riboprobes : for a1 globin and growth hormone. Fragments protected were 
separated on 5% polyacrylarnide gels and quantified by scintillation counting of 
excised portions of the dried gel using an LKB flat-bed scintillation counter 
(Pharmacia-Wallac, Turku, Finland). 
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4.2.5 Nuclear extract preparation: 
Nuclear extracts were prepared using a protocol derived from those of Dignam 
et al (187) and Kamakaka et al (188). In outline, after parallel normoxic and 
hypoxic incubations, 1-5 x 10
7 cells were harvested in phosphate buffered saline 
with EDTA and resuspended in hypotonic buffer (IO~ NaHEPES, 5mM 
MgCb, lOmM KCI, 0.5mM DTT, O.lmM EDTA and 0.2mM 
phenylmethylsulfonyl fluroride (PMSF)). Cells were then lysed by brief 
ultrasonification (10 Watts for 0.5 seconds, Soniprobe, Lucas Dawe Ultrasonics, 
London), such that. 85% of cells .took up trypan blue. The nuclear pellet . was 
mixed with an equal volume of extraction buffer (27mM NaHEPES, 1 OmM 
MgCb, 300mM KCI, 3.2mMDTT, O. lmM EDTA, lmM benzamidine, 0.2mM 
PMSF, lOOmM NaF, 1.33 µg/ml aprotinin, 0.2 µg/ml leupeptin, 0.2 ~Lg/ml 
pepstatin, 0.2 ~Lg/ml bestatin and 16% glycerol) and agitated gently for 20 
minutes at 4°C. The mix was centrifuged at 100000g for 30 minutes, the pellet 




of protein, used directly as a nuclear extract or stored in 
ALIQUOTS in liquid ~trogen. 
I 
4.2.6 Dnasel Protection Assays: 
Restriction fragments containing the Epo enchancer region were selected such 
I ' 
that either end could be end-labelled by DNA polymerase I (Kienow fragment) 
in the presence of [a.-
32P]dCTP and used as probes. The probe (1.5 x 104 cpm), 
approximately 50 µg of nuclear extra6t, and 0.5 µg of poly (dl/dC) were 
I 
' 
incubated on ice for 15 minutes in 6% glycerol. The final concentrations of 
reagents in the reaction were 25 mM NaHEPES, 1.0mM EDTA, 3.5mM 
MgCh, 30 mM KCI, 10 mM NaF, 0.7 mM DTT, 0.25mM PMSF, 5 mM 
benzamidine, lOmM glycerophosphate, 2 mM levamisole, 0.1 ~Lg/ml aprotinin. 
Various amounts of DNasel (type IV from bovine pancreas, Sigma) diluted in 
1 OmM TRIS pH 8, were then added with CaCh (2mM final concentration). 
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After a 2 minute incubation on ice, 500µ1 of stop solution (0.11 % SDS, 5.5 mM 
EDT A, and 333 mM NaCl) was added. Samples . were extracted with 
phenol/chloroform and chloroform, precipitated in ethanol, and washed with 
80% ethanol. Pellets were redissolved in 80% formamide running buffer and 
separated by denaturing PAGE (5% acrylamide) prior to autoradiography. 
4.3 RESULTS: 
4.3.1 Deletion Analysis of the Enhancer in Different Cell Lines: 
The minimal enhancer sequenc;e required for . activity in different cell lines was 
determined by deletion analysis. Results are shown in Figure 4.3 . In both HepG2 
and a23 cells active enhancer sequence was sharply delineated close to the Apal 
site at the 5' end of the enhancer, but at the 3' end the boundary of active 
sequence was less clear. In contrast to the HepG2 cells, the sequence between 1-
80 appeared to be more active (150% of the full length enhancer) than sequence 
1-96 i~n the a23 cells and a greater proportion of the full length enhancer activity 
I • 
was r~tained in the shorter 5' sequences. 
I 
I 
4.3.2 Mutation Analysis of the Enhancer Region: 
To identify critical regions within the enhancer, and to compare these sites in 
different cell lines, systematic mutations were made in the 5' region of th~ 
enhancer which was necessary for function in both HepG2 and a23 cell lines. 
Thus, 12 consecutive four base pair mutations were made in 48 bases lying 3' to 
' ' 
the Apal site (Figure 4.4a,b). In each plasmid a 153bp Bgfll- PvuIT restriction 
fragment containing the mutated enhancer was ligated into the polylinker 
sequence of pBSa- lying 1.4 Kb 5' to the a 1 globin reporter. Plasmids 
containing wild type or mutated sequences were then transiently transfected into 
HepG2 and a23 cells. 
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Figure 4.3: Effects of deletions on enhancer function in HepG2 cells and a23 cells. To 
permit direct comparison of. function, plasmids containing the truncated enhancer 
sequences specified, no enhancer or the full length enhancer were transfected in parallel 
into aliquots of cells from the same pool. Transfected cells ; were divided for parallel 
normoxic and hypoxic incubation. In each transfection, expression of the test plasmids 
was related to a co-transfected control plasmid (FGH). The results shown are the 
mean±SD of at least three independent transfections. No enhancer activity was observed 
in normoxic cells . The degree of hypoxic induction conferred by truncated sequences 
from the enhancer is expressed as a percentage of the full length enhancer in each set of 
experiments. In both HepG2 cells and a23 cells deletions of nucleotides 1-25 severely 
reduced the enhancer function. More gradual loss of function was observed with 
deletions at the 3' end, where the effect of deletions differed between the cell types . 
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In each transfection experiment, a single pool of cells was split to permit parallel 
transfections with plasmids containing no enhancer, the wild type enhancer and 
the mutated enhancers. After transfection, the cells were split for parallel 
normoxic and hypoxic incubations. This made it possible to compare directly the 
level of induction conveyed by wild type and mutated enhancer sequence (Figure 
4.4). In these transfections, no constitutive action of the enhancer was observed 
! 
in either a23 cells or HepG2 cells. Inducible activity of the wild type enhancer 
was greater in HepG2 than in a23 cells (8-17 fold compared with 3-5 fold), but 
the effect of mutations was very similar. In each cell type, nucleotide . 
substitutions in three regions corresponding {o the ' mutations in plasmids 
2,3,6,9, 10 and 11 resulted in severe reduction of enhancer function. In contrast, 
mutations in plasmids 4,5 and 7 had little effect on activity in either cell type. 
4.3.3 DNasel protection analysis of the enhancer sequences: 
To analyse further the structure of the enhancer, DNaseI protection assays were 
I 
performed using nucleat proteins extracted from HepG2 and a23 cells following 
' 
parallel incubation under normoxia and hypoxia. 
! 
Figure 4. 5 shows the results obtained usmg a probe labelled 5' to the 
functionally defined sequence. Using nuclear extracts from HepG2 cells, striking 
protection of nucleotides 28 to 49 was observed. This area was also protected 
when nuclear extract from a23 cells was used, although the protected region 
extended further 3' and covered nucleotides 28 to 66. Iri both cell types a 
hypersensitive site was observed at nuclebtide 23 . Another area of protection 
was observed in the 5' region of the enhancer covering nucleotide -11 to 9 
relative to the ApaI site. When equal concentrations of extracts from 
normoxically and hypoxically incubated cells of each type were compared no 
change in the extent or degree of DNaseI protection was seen. 
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4.3.4 Functional Analysis of subsequences: 
Since subsequences within enhancer may operate independently when placed 
close to a promoter or when re-iterated, further expression studies were 
performed using such elements placed immediately 5' to the SV40 promoter. 
First, the operation of elements consisting of nucleotides 1-25 and 25-60 was 
compared. Nucleotides 1-25 contain the two ctjtical regions defined by mutants 
2,3 and 6, whereas nucleotides 25-60 contain a direct repeat sequence 
TGACCTCTTGACCC resembling a steroid/thyroid receptor binding element 
and defined as functionally important by mutants 9-11 (Figure 4.4). When 
expressed in HepG2 cells, hypoxic expression was induced with the plasmids 
containing sequence 1-25 adjacent to the SV 40 promoter but not with those 
containing sequence 25-60. This difference was most marked when concatamers 
of these sequences were compared (Figure 4.6). Re-iteration of sequence 1-25 
resulted in large increases in the amplitude of hypoxic induction, whilst 
expression in hypoxic HepG2 exceeding that of control plasmid containing the 
I 
SV40 promoter alone by a factor approaching 100 fold. In contrast, re-iterations 
I 
of I sequence 25-60 produced no inducible expres$ion in hypoxic HepG2 cells 
I 
(Figure 4.6). 
When these plasmids were expressed in a23 cells, the pattern of expression was 
very similar. Activity resided' in sequence 1-25 but not in sequence · 25-60, 
although the level of induction was not as great as that observed in HepG2 cells 
(Figure 4.6). 
Also of interest is comparison of sequence 1-60 with sequence 1-25 when placed 
adjacent to the SV 40 promoter. In both HepG2 and a23 cells there was an 
increase in inducible activity of sequence 1-60 when compared with sequence 1-
25. 
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Figure 4.4b 
Figure 4.4.a,b: Mutational analysis of the mouse Epo enhancer. Mutations define 3 critical regions in 
nucleotides 1-48 of the mouse erythropoietin enhancer . . Mutations were made in a 153 bp Bglll-Pvull 
fragment from the mouse erythropoietin enhancer locus which was placed 1.4 kb from the a.1 globin 
promoter (see Figure 4.2) Nucleotide substitutions are indicated. Plasmids containing the enhancer · 
m~tations, no enhancer or the ~utated enhancer were transfected in parallel into aliquots of cells from the 
same pool. Transfected cells were divided for parallel normoxic and hypoxic incubation. No enhancer 
activity was observed in normoxic cells. Hypoxia inducible activity of the mutant enhancers is expressed as a 
. % of that of the unmutated enhancer. Data shown are the mean±SD of three independent experiments. 
Mutations have similar effects on function in HepG2 cells and a23 cells. In each cell type mutations of 
nucleotide 5-12, 21-24 and 33-24 caused severe reduction, or complete ablation, of function. In HepG2 cells 
inducible activity of the unmutated enhancer was greater than in a23 cells, values varying from 8-17 and 3-
5, respectively. 
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Figure 4.5 DNAsel protection analysis of 
the mouse erythropoietin enhancer. The 5' 
end-labelled probe was a 484 bp Bglll-Sphl 
fragment contammg the mouse 
erythropoietin enhancer linked to polyli°nker 96 
sequence from pBluescript SK.II. Nuclear 
extract was prepared after parallel 16 h 
66 incubations of cells in normoxia, 21 % 0 2 
(N) and hypoxia, 1 % 0 2 (H). Lane 1, no 
extract; lanes 2 and 3, 50 µg of extract from 49 
normoxic and hypoxic HepG2 cells; lanes 4 
and 5, 50 µg of extract from normoxic and 
hypoxic a23 cells. Lane 6' is a Maxam and 28 
Gilbert G + A column from the same probe. 23 
The .regions protected are indicated using - -
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Figure 4.6 Action of subsequences from the mouse erythropoietin enhancer on an adjacent SV40 promoter. The structure of the test plasmids 
is shown in (A), where E represents erythropoietin enhancer ~quence, SV40P represents the SV40 early promoter and GH represent the body 
of the growth hormone gene. The erythropoietin enhancer sequence fragment (E) used in each test plasmid is indicated beneath the 
corresponding bars of the histogram and is numbered as in Fig 4.2. A co-transfected plasmid containing the a 1 globin gene alone (pBSct") was 
used to correct for transfection efficiency. Expression is normalised to that of the enhancerless pSVGH in normoxic cells and represents the 
mean±sD of three independent experiments (B). Inducible activity was conveyed by sequence (25-60) in any cell type. Concatamers of this 
sequence were tested in either orientation (25-60)3 and (60-25). but none had any action. The monomeric sequence, 1-60, was more active 
than the monomeric sequence, 1-25 in both HepG2 and a23 cells. 
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Since mutation analysis had indicated the existence of two critical regions within · 
the sequence 1-25, short sequences including each of these sites were inserted 
either as monomers or multimers adjacent to the SV40 promoter and expressed 
in HepG2 cells. The two sequences 4-15 and 16-27 were also rejoined using an 
8bp spacer, (4-15) TCTAGTCC (16-27). None of_ these sequences conveyed 
activity wh1n expressed in HepG2 cells (Table 4.1) 
Table 4.1 Activity of short sequences either as monomers or multimers within the 
critical regions of the Epo enhancer. The sequences were inserted adjacent to the SV40 
promoter and expressed in HepG2 cells. None of these sequences displayed activity. 
! 
CONSTRUCT CONSTITUTIVE HYPOXIC/NORMOXIC 
Control 1.00 1.46 
(4-15) 1.04 1.41 
(4-15) X 2 0.69 1.40 
(4-15) X 4 0.76 1.31 
(4-15) (15-4) 0.76 1.39 
(15-4) X 2 ! 0.92 1.24 
(27-16) X 2 I 0.92 1.24 
(16-27) X 5 ! 0.82 1.49 
(4-15)N8(16-27) 1.20 ! 0.92 
4.3.5 Effect of distance from a promoter: 
While both deletion and mutation analysis m HepG2 cells .indicated that 
sequences 3' to nucleotide 25 were obligatory for enhancer function when 
placed 1.4 kb from the a.1 globin promoter, these sequences were not obligatory 
i • 
and had no activity when placed :adjacent to an SV40 promoter. To distinguish 
whether this difference was a function of distance from the promoter or some 
specific aspect of the promoter sequence, expression of plasmids containing 
subsequence 1-25 or subsequence 1-96 approximately 0.1 and 1.4 kb from the 
a.1 globin promoter was compared. In HepG2 cells, sequence 1-96 was almost 
equally active in both positions whereas subsequence 1-25 was only active close 
to the promoter (Figure 4.7). 
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Control 1-25 1-96 Control 1-25 1-96 
Figure 4. 7 Effect of distance from a promoter on function of the mouse erythropoietin 
enhancer. The structure of the test plasmids which were used in these experiments are 
shown (A). The pairs of plasmids were identical except that one contained 124 bp 5' 
flanking sequence from the a.1 globin gene and the other contained 1.4 kb of this 
sequence separating the enhancer from the a.1 globin promoter. A plasmid (FGH) was 
co-transfected to control for variations in transfection efficiency, RNA synthesis and 
RNA recovery. Transfected cell were divided for parallel normoxic and hypoxic 
incubation. (B) Normoxic and hypoxic expression of the test plasmid were normalised 
with respect to expression of the control plasmid. The values plotted represent the ratio 
of normalised hypoxic to normoxic expression from three separate transfections 
(mean±SD). In HepG2 cells nucleotides 25-96 were necessary for enhancer function at a 
distance from the a.1 globin promoter but not when the enhancer was close to the 
promoter. 
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4.4 Discussion 
Deletion of sequence close to the Apal site at the 5' end of the mouse Epo 
enhancer (construct 8-96, Figure 4.3) sharply reduced enhancer activity 
indicating that these 88 nucleotides contained bases critical for inducible 
enhancer operation. However the length of the minimal functional enhancer 
indicated that enhancer function was most probably dependent on several other 
critical sequences. This was borne out by mutational analysis of the first 48 
nucleotides (Figure 4.4) .which defined three critical sites corresponding to 
nucleotides 5-12, 21-24 and 33-44. The sequences represented by 5-12 and 21-
' ' 
24 do not have ·homology with other known transcription factor binding motifs. 
! 
Mutations affecting nucleotides 33-44 disrupt the sequence 
TGACCTCTTGACCC which may represent . a binding site for an orphan 
receptor of the steroid/thyroid hormone family (120). 
The constructs used in these experiments contained the enhancer element 
I 
separated from the a 1 globip promoter by 1.4 kb. All 3 regions within the 
, I 
enhancer were necessary fo~ function in this setting. It has been shown that 
isolated sequences within enh~ncers which are inactive when placed at a distance 
form a promoter may operate when re-iterated or placed close to the promoter 
(183,189,190). To test the subsequences individually for their ability to convey 
inducible responses we therefore placed monomers or concatamers of each 
' . 
element adjacent to the SV40 promoter. 
Concatamers of nucleotides 1-25, which contained the 5' critical sites, but 
: 
neither of the TGACCC/T half sites, were compared directly with concatamers 
of nucleotides 25-60, containing the TGACCC/T direct repeat. The behaviour of 
the two regions was quite different. Concatamers of nucleotides 1-25 were 
highly active and showed inducible activity which was substantially greater than 
even the full length enhancer. In contrast, neither monomers nor concatamers of 
nucleotides 25-60 showed any inducible activity. 
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The independent operation of nucleotides 1-25 in the pSVGH plasmids was 
confirmed by the inducible operation of this sequence in pBS.1.a. 1-25, which 
contained a different heterologous promoter and reporter gene. The two critical 
subsequences within this region indicated by mutation of nucleotides 5~12 and 
21-24 did not appear to function independently since a variety of concatamers of 
nucleotides 4-15 or 15-27 were not functional. Furthermore, introduction of 
l 
spacing nucleotides TCTAGTCC in construct 4-15(Ns)16-27 ablated function . 
Thus, this study defines the inducible operation of a 25 nucleotide sequence 
containing two sites which are critical for function. 
Studies on the human Epo enha_ncer, have shown that mutations in two regions 
of the enhancer can destroy function (119,120). The mutated region of the 
mouse Epo enhancer was somewhat more extensive and covered the regions that 
are homologous to both of those examined in the human studies. 
Despite the use cif a different system of nucleotide substitution, the results are 
' i 
entirely consistent with the experimental observations in each of the studies of 
the human enhancer. The critical regions defined by mutations 2-3 and 6 
correspond to sequences designated BS-I and BS-2 in one .study (119) whereas 
mutations 9-11 affect the directly repeated TGACCC/T half sites which were 
. ' 
' 
shown to be critical for function in the other study (120).Thus at least 3 
functionally critical regions have been identified in murine and human Epo 
enhancers that control Epo gene expression. 
Different conclusions were reached in the two studies on the human enhancer as 
to the function of each region. Blanchard et al (120) argued that the directly 
repeated half-sites were the critical site of interaction, and postulated that 
modification of a factor at this site mediated the oxygen regulated response. In 
contrast, Semenza and Wang (119) demonstrated an inducible DNA binding 
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activity using an oligonucleotide from the 5' region of the enhancer, and found a 
33bp oligonucleotide extending to include only 4bp of one of the directly 
repeated half-sites retained some inducible activity which could be restored to 
the level shown by the full length enhancer by re-iteration. They postulated that 
the inducible interaction took place with sites at the 5' end of the enhancer with 
the direct repeat element functioning to amplify the response. This study 
supports the latter explanation in that concatamerization of the subsequence 1-
25 resulted in a marked increase in activity. · 
I 
When the non-erythropoietin producing a23 cells are compared with HepG2 
cells the same two critical sites were necessary for function in the 5' region of 
the enhancer. Furthermore, in both HepG2 and a23 cells, sequences lying 3' to 
this region were important for operation at a distance, amplified the response 
when the enhancer sequence was close to the promoter, but did not function 
independently. Maxwell et al (121) showed th~t inducible operation of the 
I 
mouse Epo enhancer in Epo non-producing cell li~es was distinct from other cell 
s~ress responses such as heat chock, and resembteb the inducible response of the 
I 
native · Epo gene in hepatoma cells. They argued that a similar or identical 
mechanism of oxygen sensing and signal transduction must operate widely, most 
prob~bly inducing the expression of other genes in non-Epo producing cells. 
Such a system could induce gene expression by activation of a variety of 
transcription factors which might vary between different cell types and recognise 
different motifs in cis-acting regulatory sequences (182,183). However, in this 
study, the demonstration that similar subsequences within the Epo enhancer 
were critical for function in different cell lines strongly suggest that common 
factors are operating this response in different cell lines. 
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In the DNAseI protection assays inducible changes were not observed in 
protection of the critical sequences in the 5' region of the murine enhancer and 
at similar sites in recent analysis of the human Epo enhancer (119). 
I 
However, using electrophoretic mobility shift assays, Semenza and Wang have 
observed inducible binding of a nuclear factor from Hep3B cells, which they 
' 
designated HIF-1 (hypoxia inducible factor), to nucleotides 3-21 of the human 
enhancer (119). In this study, the results are consistent with the binding of such 
a factor to the mouse Ep,o enhancer and strongly suggest that it operates in 
erythropoietin non-producing cell lines. This DNA binding protein has now been 
characterized (191). It is made up of four polypeptides composed of two 
different subunits: 120kda HIF-1 alpha and 91-94kda HIF-1 beta. HIF-1 was 
shown to bind specifically to the wild type of the Epo enhancer in Hep3B cells 
but not to the mutant sequence that lacks hypoxia-inducible enhancer activity. It 
was also shown to operate in the non-Epo producing HeLa S3 cells suggesting 
a general, role of HIF-1 in hypoxia signal transduction and transcriptional 
regulation. 
I 
Using nuclear extract from HepG2 cells in DNAseI footprinting studies, ~triking 
non-inducible protection of nucleotides 29-59, which include the TGACCC/T 
. repeat element, was observed. This footprint was closely similar to that 
described on the human enhancer using extract from Hep3B cells (119,120). 
However, a larger footprint extending over a further 18 nucleotides 3' to this 
region was observed in a23 . Although this indicates differences in the DNA-
protein interactions with the 3' end of the enhancer it does not fully explain the 
functional data. For instance, deletion analysis in HepG2 cells implicated 
functionally important sequences lying 3' to nucleotides 50 which were 
necessary for enhancer operation at a distance, but which were not protected. It 
therefore appears that, in addition to the TGACCC/T direct repeat, further 
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subsequences in the 3' region of the enhancer modulate the function of the 
inducible element. Precise definition of these sequences and their interactions 
will require further work. 
.Based on responses obtained by exposure of hepatoma cells to transition 
elements, haem synthesis inhibitors, and haem protein ligands such as carbon 
' . 
monoxide, Goldberg et al (IO 1) proposed that the oxygen sensor controlling 
Epo production by hepatoma cells might be a haem protein. Recently, Yoshioka 
showed that nitric oxide synthase (NOS) itself has a haem moiety in its stru'cture. 
Furthermore, NOS is stimulated by TNFa and NO may be one mediator of 
cytokine-induced haematopoietic suppression (180); the NO/guanosine 3'5' . 
cyclic monophosphate system plays an important role in oxygen sensing and 
hypoxic regulation ofEpo production (109). Thus it can be postulated that in an 
inflammatory/infective process where both TNFa and NO are released, TNFa 
may disrupt the interaction of transcription factors with critical sites on the 
I 
enhancer elellJent thereby inhibiting to some extent the activati1n of transcription 




Tuberculosis is acquiring increasing importance throughout the world especially with the 
advent of human immunodeficiency virus (HIV) infections. In South Africa, tuberculosis 
i 
is a major cause of morbidity and mortality. 
The anaenua associated with the disease contributes greatly to the morbidity. The 
anaemia can be categorised biochemically as anaemia of chronic disorders in that serum 
iron is low, the ;, transferrin is decreased and iron stores are adequate or raised. 
Understanding the pathophysiology of this anaemia js important in that it would ·explain 
how inflammation causes anaemia and perhaps therapeutic options or avenues by which 
this anaemia can be treated. 
The anaenua of pulmonary tuberculosis is associated with a disturbance of iron 
metabolism and erythropoietin production. These findings are in agreement with that of 
the anaemia associated with rheumatoid arthritis (146), cancer (148), HIV (149) and 
Crohn's disease (16.3). In this stu9y (Chapter 2), it was clearly shown that anaemia 
develops in pulmo~ary tuberculosis as a result of the degree of inflammation sinde the 
level of C-reactive protein was significantly higher in the anaemic compared to the non-
anaemic !PTB group. Furthermore, with anti-tuberculous therapy, there was a significant 
decline in the. level of CRP in the anaemic PTB group which resulted in normalization of 
the haemoglobin an1 iron levels y.,ithin three months of initiation of therapy. For the 
same degree of anaemia, patients with pure iron deficiency anaemia mounted a 
significantly greater Epo response compared to the anaemic PTB patients. It appears, 
therefore, that PTB-related inflammation releases a substance or substances that interf~re 
with the production of Epo. 
To investigate these findings further, measurements of production of the endogenous 
cytokine TNFa. from PBMC's of patients with PTB (anaemic and non-anaemic) and iron 
deficiency anaemia were undertaken (Chapter 3). 
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. Patients in the anaenuc PTB group produced significantly higher levels of TNFa 
compared to patients in the non-anaemic PTB and iron deficiency groups. These findings 
correlated well with the fact that the anaemic PTB group had the greatest degree of 
inflammation as shown by the higher CRP level. To determine the effect of TNFa on 
Epo production, the moi:iocyte supernatants from the the three groups were added to 
HepG2 cells in culture. ~he production of Epo by these cells were markedly inhibited by 
the supernatants from the anaemic PTB group. Furthermore, this inhibition could be 
reversed by the use of anti-TNFa-specific antibodies. These findings are in agreement 
with that of Faquin efal (152). Jelkmann et al (153). Unlike these studies, however, we 
employed endogenously produced TNFa rather than a recombinant TNFa and we 
clearly showed reversal of inpibition with the anti-TNFa antibodies. 
In anaemic f PTB there was an inverse relationship between the Hb level and Epo 
production (Chapter 2). In iron deficiency anaemia, however, for the same degree of 
anaemia, the production of Epo was markedly increased compared to that of PTB. Thi~ 
I 
• i 
suggested that hypoxia as a result of anaemia in PTB did not result in an adequate Epq 
, I j 
response perhaps due to TNFa interferance with the oxygen sensing mechanism. TNFa! 
is known to stimulate the production of NO (108). In inflammatory/infective states both 
NO and TNFa are released . and it has been shown that the NO/cGMP system play an 
important role in oxygen sensing and hypo~c regulation of Epo production ( 111 ). In an 
' . . 
attempt to study the oxygen sensing mechanism further, it was decided to investigate the 
regulation of the Epo gene. 
Tranfection studies in HepG2 and Hep3B cells have defined an oxygen regulated 
enhancer commencing 120 bp 3' to the poly A addition site of the human and mouse Epo 
genes (116-120). In this study (Chapter 4) the enhancer element was subjected to 
mutational analysis in an attempt to define the critical sites on the enhancer involved in 
oxygen sensmg. In agreement with Pugh et al (118), Semenza et al (119) and Blanchard 
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et al (120), we have identified a 25 nucleotide enhancer element in the 3 '-untranslated 
region of the mouse Epo gene which confired oxygen sensing in both Epo and non-Epo 
producing cell lines. The enhancer element can be divided into three functionally 
important domains (Figure 5 .1 ). 
1 25 48 
GGGCCCTA~GTGCTGCCTCGCATGGCCCGGCTGACTCTTGACCCCTCTGGGCTTGAGGCCA 
Apa I ::t:)ffH'H':'tt:'H n:==t:::=r ftt:t?t:t:=:m':'?'?t:t:t? 
Figure 5.1: DNA sequence of the mouse Epo enhancer showing functionally important domains :, 
involved in oxygen' sensing (shaded area). 
Mutation of these three domains resulted in ablation of the oxygen sensing capacity of . 
the enhancer element. An explanation for this ablation of activity could be due to binding 
of transcriptional repressors to these critical sites. DNase footprint analysis revealed that 
although transcription factors bound to these regions (Figures 4.5 & 5.2), there was no 
difference between normoxia and hypoxia (Figure 4.5), thus ruling out the possibility of 
altered transcription factor binding. 
Bgl II . Apa I 
-11 I 9 
AGATCTGGGAAACCAGAGGTGGAGGGGGTTGGGCCCTACGTGCTGCCTCGCA 
I (HepG2/a23) II (HepG2/a23) 




Figure 5.2: DNA sequence of mouse Epo enhancer showing protected regions by DNase 
footprint analysis (shaded area). In both HepG2 and a23 cells regions I and II are 
identical. Region III in a23 is protected between nucleotides 23 and 66 while in HepG2 
cells protection is between nucleotides 23 and 49 . 
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It is conceivable, however, that different proteins with different functional activities bind 
to the same element, thereby changing the transcriptional activity of the gene. Further 
proof of this will only come from experiments attempted at purifying these transcription 
factors . Semenza and Wang isolated a nuclear factor from Hep3B cells (HIF I) which 
they showed binds to nucleotides 3-21 of the human Epo enhancer (119). This factor 
binds to the wild type of the enhancer but not to the mutated sequence (19;1). It was also 
shown to be present in the non-Epo producing HeLa S3 cells (191). The results obtained 
in this study, are consistent with the binding of such a factor to the mouse Epo enhancer 
and strongly suggest that it operates in the non-Epo producing a~3 cells. 
TNFa. could inhibit Epo production in one of ( or a combination of) different pathways. 
One such mechanism could be that TNFa. inhibits the production of a transcription factor 
that bind to these elements. Alternatively, it could stimulate the production of a negative 
transcription factor, such as that reported by Beru et al (113). A more likely explanation 
for action of TNFa. could be modification of transcription factors via the a9tivation of 
i 
signal transduction pathways for example phosphorylation of transcription factor is 
kndwn to affect DNA binding activity (192). 
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DIAGNOSTIC CRITERIA FOR PULMONARY TUBERCULOSIS 
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Therapeutic Clinical Trial 
Subcategory 
1. Lesion (s) in upper or lower lobe apical 
segment (s): 
A. Infiltration or scarring with cavitation 
B. Non-confluent infiltration or scarring 
without cavitation 
2. Lesion (s) elsewhere in the lung (not 
apico-posterior) 
A. with cavitation 
B. without cavitation 
3. Diffuse lung lesions: 
A. Miliary 
B. Non-Miliary 
4. Pleural lesion (s) 
A. Pleural effusion (s) 
5. Lesion (s) in upper or lower lobe apical 
segment which is new or enlarging 
and shows no sign of resolution on 
a 2-month follow-up radiograph 











B. Twice 7 
· C. 3 times 10 
2. Culture positive for Mycobacterium tuberculosis 
A. Once 7 
B. Twice 
1. Heaf grade 3 
2. Heaf grade 4 
1. Lung, liver or lymph node 
A. Epitheloid/giant cell granuloma 
B. Granuloma with necrosis 
C. Granuloma with AFB's 
2. Pleura 
A. Epitheloid giant cell granuloma 
1. Radiological improvement after 2 months 
of treatment as compared with the chest radio graph 









NOTE: A total score of 10 is required for the diagnosis of active pulmonary 
tuberculosis, but only 1 score may be used from each category. 
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BIOCHEMICAL AND HAEMATOLOGICAL PARAMETERS OF 
PATIENTS AND HEAL THY VOLUNTEERS 
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NORMAL RANGES 
(According to the Haematology and Biochemical laboratories of 
Groote Schuur Hospital Cape Town) 
Haematology Biochemistry 
Hb (m) 133-173g/L Na+ 135-145 mmol/L 
(f) 116-156 g/L K+ 3.5-5 .5 mmol/L 
MCV(m) 81-93 fl Urea 1.7-6.7 mmol/L 
(f) 81-95£1 Cr 75-115 µmol/L 
MCH 28-30 pg S-Ferritin 20-200 µg/L 
Hct (m) 40-50 % RC-Ferritin 0.002-0.02 fg/cell 
(f) 35-45 % 
wee 4-11 xl09/L S-Iron 9-30 µmol/L 
S-Folate > 2.5 ng/ml TIBC 45-65 
' i 
RC-Foltate 230-710 ng/ml % Sats 20-50 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PEER _REVIEWED PAPERS 
Blunted Erythropoietin Response to Anaemia in Pulmonary Tuberculosis 
All clinical and experimental work elucidated in this paper was done entirely by me. 
Characterisation of functional domains within the mouse erythropoietin 3' 
enhancer conveying oxygen-regulated responses in difTerent cell lines 
All experimental work on HepG2 and a23 cells elucidated in this paper were carried out 
entir~ly by me. Written permission was obtained from Dr P Ratcliffe, Head of the 
Erythropoietin Research Group, to publish the work;in this thesis. 
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Blunted erythropoietin response to anaemia 
in tuberculosis 
Ebrahim 0, Folb PI, Robson SC, Jacobs P. Blunted erythropoietin 
response to anaemia in tuberculosis . 
Eur J Haematol 1995: 55: 251-254. © l\[unksgaard 1995. 
Abstract: The precise cause of the anaemia that is commonly associated 
with severe pulmonary tuberculosis (PTB) has not been elucidated. The role 
of erythropoietin (Epo), the central hormone regulating red cdl formation, 
still awaits clarification. We therefore determined serum Epo levels in patients 
with PTB; group l, haemoglobin less than 110 g/L, group 2, haemoglobin 
greater than 110 giL; group 3, controls, consisted of matched individuals with 
uncomplicated iron deficiency; group 4, healthy volunteers. Peripheral 
blood monocytes were obtained from patients with PTB and the controls, 
cultured, and the supernatant fluid (SNF) harvested. Tumour necrosis factor 
alpha (TNF:.t) levels were determined in the SNF, which were then added 
in various dilutions to a hepatocellular carcinoma cell line (HepG2) capable 
of regulated EPO synthesis i11 rirro. The influence of this cytokine was 
defined by the addition of specific neutralising anti-TNF:t antibodies in 
this assay system. Patients in group I had significantly lower Epo levels 
(54± 11 mU/mL) compared with those in group 3 (142±41 mU/mL) 
{p < 0.0 !). Monocyte supernatants from patients in the anaemic PTB group 
had markedly elevated TNF:.t levels and significantly suppressed Epo 
output by HepG2 cells in rirro (p < 0.0 !). This inhibition wa~ consistently 
abrogated by anti-TNF:i antibodies. 1Serum Epo levels were inappropriately 
low in untreated PTB patients when compared with corresponding 
haemoglobin levels in iron deficient controls. This blunted response could 
be ascribed to release of TNF:t or other cytokines by activated monocytes. 
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The subnorma.1 haemoglobin level associated with 
severe pulmonary tuberculosis (PTB) is considered 
to be multifactorial and attributable to the underly-
ing chronic inflammatory disorder ( I, 2). Disturb-
ances in iron metabolism (3), decreased red cell sur-
vival ( 4), and reduced erythropoietin (Epo) responses 
(5) have been described in the pathogenesis of this 
anaemia. Although both impaired production and 
response to Epo may contribute to the reduced red 
cell mass (6-10), a single mechanism has not been 
identified. 
able in part of TNF::t (14), which also exerts an in-
hibitory effect on haematopoiesis, both i11 i·itro (15) 
and in 1-fro (16) and suppresses the production of 
Epo in a human hepatocellular line, HepG2, in ritro 
(I 7, 18). 
Mycobacterial lipoarabinomannan is a potent trig-
ger of tumour necrosis factor alpha (TNF:t) release 
from monocyte-macrophages ( 11 ), with its produc-
tion in the distinctive granulomata being considered 
an essential component of the immune response to 
mycobacterial infections ( 12), while peripheral blood 
mononuclear cells (PBMC) from these patients are 
known to release large quantities of TN F:.t in rirro 
(13). The fever, weight loss and tissue injury that 
characterise advanced tuberculosis may be attribut-
In further studying these interrelationships, we 
have demonstrated suboptimal Epo plasma levels 
for the degree of anaemia associated with PTB and 
we present i11 rirro data indicating that mycobacterial 
infection induces monocyte release of TNF:i: . On 
this basis, we advance the hypothesis that increased 
output of this inhibitory cytokine blunt.s ~h~ synthe-
sis or release of the hormone, · so that 1t 1s mappro-
priately low for the haemoglobin concentration in 
these individuals. 
Material and methods 
Patients 
Four groups, each of IO subjects, were studied. 
Group 1 comprised newly diagnosed non-pregnant 
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individuals with ·PTB, haemoglobin below l 10 g/ l, 
and having no apparent dissemination or other as-
sociated svstemic illnesses. Group 2 were age- and 
sex-match~d PTB patients with haemoglobin levels 
greater than 110 g/L. Group J consisted of other-
wise healthy people with demonstrated absolute iron 
deficiency anaemia due to menorrhagia (n = 3), gas-
trointestinal tract bleeding not caused by an under-
lying malignancy (n = 4): or to e:<cessi\·e blood do-
nations (n = 3). The haemoglobins in this group 
corresponded to those in group I. Group 4 consisted 
of 10 healthy non-anaemic volunteers. 
The study was carried out according to the re-
quirements of the Declaration of Helsinki and with 
the approval of the Ethics Committee of the Uni-
versity of Cape Town Medical School. 
' 
Laboratory studies 
These included full blood and differential count ( 19), 
biochemical profile (SMAC II autoanalyser, Tech-
nicon, Tarrytown, USA) and C-reactive protein 
(CRP), estimated quantitatively by immunoditTusion 
(20). Serum and red blood cell folate and serum 
vitamin B 12 levels (Radioimmunoassay, Amersham 
International), serum iron levels, total iron binding 
capacity of the blood (21) and serum ferritin ,vere 
determined according to standard methods. Serum 
Epo levels were determined by established radio-
immunoassay (Incstar EPO-TRAC RIA, Minne-
sota, USA). 
Cell cultures 
Blood samples from PTB patients and iron deficient 
controls were diluted L/L (vol/vol) in calcium-free 
Hanks' buffered saline solution (HBSS), supple-
mented with 0.08 % EDTA, and the mononuclear 
cells were isolated by density centrifugation on lym-
phoprep (Highveld Biologicals, South Africa). Ad-
herent mononuclear cells \Vere cultured for 4S hours 
(13) and the cell-free supernatant fractions (SNF) 
were frozen at - 70°C until analysed for TNF:t by 
immunoradiometric assay (Amersham IRMA kit); 
no deterioration in activity occurs under these con-
ditions. 
HepG2 cells that had been evaluated and stan-
dardised (Department of .Medical Biochemistry, 
Medical School, University of Cape Town; obtained 
through American Type Culture Collection) were 
plated on 24-well polystyrol dishes (linbro Brand, 
Flow Laboratories, Mclean, Virginia, USA) and 
cultured in modified Eagles' medium (J\,f EM) with 
10% foetal calf serum (Highveld Biologicals, South 
Africa). The cells were incubated at 37 = C in humidi-
fied air, \vith 5 ~,~ CO~ confluent. The media were 
then removed and va-rious dilutions of monocyte 
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SNF from patients and controls were addt:d to the 
cells. The HepG2 cells were incubated for a further 
24 hours, after which the SN F was removed and 
stored at - 70 = C until analysis of the Epo. The cells 
were washed with phosphate-buffered saline and 
lysed with SDS-NaOH (sodium dodecyl sulphate 
5 g/L in NaOH 0.1 mol/L). Total cellular protein 
was determined by the automated Bio-Rad dye bind-
ing microassay system (22). Samples were diluted 
50-fold prior to assay in order to minimise any in-
terference by SDS-NaOH. Epo levels were then ex-
pressed as m U /mg cellular protein. 
Dose-response studies were carried out in the 
presence and absence of specific polyclonal goat 
IgG-(H34) and monoclonal IgG (101-4) TNF:x anti-
bodies (National Biological Standards Board, Hert-
fordshire, UK) at standardised dilutions . 
Data analysis 
The i-.fann-Whitney U-test was used to compare 
haemoglobin, Epo and CRP levels between the vari-
ous gr9ups. Analysis of variance (ANOVA) was 
used for comparison of TN F~ produced by mono-
cytes and for the_ levels of Epo produced by HepG2 
cells in the presence of monocyte SN F from PTB 
patients and controls. The results are reported as 
mean (SEM). 
Results 
For matching degrees of anaemia the plasma Epo 
was significantly lower in group I than in group 3 
(p<0.01) (Fig. 1). 
Adherent PBl\·IC purified from anaemic PTB pa-
tients produced more TN F~ (770 [ 173] pg/ml) than 
e 
3 







2 3 4 
Group 
Fig. I. Comparison of haemoglobin .ind erythropoietin serum 
levels (mean± SEJ\I) in :maemic PTB patients (group I). non-
anaemic PTB patients (group 2). iron deficient controls (group J) 
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Fig. 2. Production of TNF:t by PB~IC obtained from untreated 
PTB p:itients with haemoglobin below I IO g/ L (!), or above this 
level (2) and iron deficient controls (3). Also shO\\~n are the efTc:cts 
on erythropoietin production by HepG2 cells in the presence of 
monocyte SNF from the same three groups . Dat:i represent mean 
(SEM). ("p<0.001 comparing I :ind 3). 
these cells derived from the non-anaemic patients 
( 431 [ 90] pg/ mL (p < 0.00 I)). The levels of this cy-
tokine were higher in the monocyte SNF from the 
latter group when compared to Group 3 (98 [ 17] 
pg/mL} {p < 0.005) (Fig. 2). The production of Epo 
by HepG2 cells was markedly inhibited in the pres-
ence of monocyte · SNF from patients in group l 
compared to both groups 2 and 3 {p < 0.001) (Fig. 2). 
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Fig. 3. The effect of specific monoclon:il (mt\b) (Figure 3a) or 
polyclon:il (p.-\b) (Figure 3b) anti-TN F:x :intibody on erythropoi-
etin (Epo) production by HepG2 cells in the presence of increas-
ing concentr:itions of monocyte SNF from anaemic PTB patients. 
D:it:i represent me:in (SEM). 
nlunted erythropoictin response 
duplicate for the individuals in each of the three 
groups compared with matched controls. 
The effects of monoclonal and polyclonal 'anti- -. 
TNF:£ antibodies on Epo production by HepG 2 cells 
in the presence of various dilutions of monocvte SNF 
were examined in the anaemic PTB group ·(Fig. 3). 
The addition of increasing concentrations of mono-
cyte SNF resulted in a progressive reduction of Epo 
produced by the HepG2 cells. In the latter, the re-
lease of the hormone was elevated at the lower con-
centrations of monocyte SNF when the cells were 
incubated in the presence of optimal saturating con-
centrations of anti-TNF:£ antibodies. The fall-off re-
flects the use of a fixed dose of antibodies, \vith 
decline at 40 \ SN F attributable to increasing avail-
ability of the inhibitory cytokine. 
Discussion 
The anaemia associated with PTB appears to be 
explicable, at least in part, by reference to inappro-
priately depressed plasma Epo levels, causally linked 
to the inflammatory process that leads to the release 
of a number of inhibitory cytokines. We found that 
in rirro production ofTNF:£ by PBMC purified from 
these patients was significantly greater than in those 
with higher haemoglobin levels and the controls. 
Furthermore, monocyte SNF from this group inhib-
ited the production of Epo by HepG2 cells in virro. 
The suppressed release of the hormone was more 
pronounced than in the non-anaemic PTB patients 
and those with iron deficiency, in keeping with the 
higher levels of TNF:t in the anaemic TB patients. 
Although the levels of this inhibitor in the non-
ahaemi~ PTB group were greater than in controls, 
no suppressive effect on Epo was observed . It ap-
pears, therefore , that a critical level of the cytokine 
may be necessary in order to block the increased 
requirememt for Epo synthesis, thus contributing to 
the anaemia. 
In certain patients suffering from -rheumatoid ar-
. thritis or cancer, administration of .recombinant · 
human Epo has resulted in improvemeJt of anaemia 
(23, 24 ). It appears that pharmacological doses of 
the hormone act directly on the marrow to stimulate 
· erythropoiesis despite ongoing suppressant effects of 
inflammation and elevated circulating cytokine lev-
els (25). 
The abrogation of the suppression of HepG 2 Epo 
released by monocyte SNF by both poly- and mono-
clonal anti-TNF antibodies implicates this specific 
cytokine in impairing Epo release in rirro. This is 
consistent with the findings of others ( 18), that the 
recombinant molecule may block the production of 
Epo by HepG 2 cells in rirro. An effect of this, and 
possibly of other cytokines, on erythropoiesis may 
explain the impaired response to anaemia in patients 
\ 
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with PTB or other chronic inflammatory conditions 
(26). 
In the HepG2 cell line and in normal human liver 
· and kidney, the production of Epo is stimulated by 
cobalt and . hypoxia; control is primarily achieved 
through modulation of mRNA levels (27) .. The 
mechanisms by which TNF:t suppresses EPO re-
lease is the focus of further study. 
ln ·conclusion, we propose that in anaemic PTB 
patients the blunted EPO response may 1be explained 
by the inhibitory effects of TN F:t release by 
monocyte-macrophages during the course of the in-
flammatory process. 
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Abstract 
We have analysed sequences \Jiithin the moust: t:rythropoietin enhanc.er which are required for <.,xygen regulated operation in 
the erythropoietin producing cdl line, HepG2, and in two non-erythropoietin producing ceU lines; the lung fibroblastoid cell lint: 
a23, and mouse el)throleukaemia (l\-1EL) cells. At least three critical sitt:s were demonstrated "ithin a 96 nucleotide sequence. 
Oxygen regulated operation was dependent on sites within the first 26 nucleotides. Sequences lying 3' to this region modulated 
enhancer function but did not themselves convey oxygen regulated operation. In HepG2 cells these 3' sequences co-operated to 
permit operation of tht: induciole element afa clistance from a promoter, but in l\·IEL cells 3' sequences repressed activity of the 
inducible element. Though operation of this 3' sequem:e differc:d according to the cell type, O.\ygen regulated operation was 
dependent on the same two critical sites in the 5' region in both erythropoietin producing and non-erythropoietin producing 
cells. These findings ·1,1..1pport the existence of a widespread oxygen sensing ::.,'l>tem in mammalian cells which is similar to that 
operating in specific cells to regulate ecythropoietin production, and they inclicate that the syste:m activates factors with similar 
DNA sequence ~pecificity in different cells. 
' Key words: Oxygen; Gene; Regulation; Eryth.ropoietin; Enhancer 
I 
1. Introduction 
Erythropoietin plays a central role in the feedback 
regulation of erythropoiesis in response to blood loss 
or reduced blood oxygenation (reviewed in Refs . . 1,2). 
E.rythropoietin synthesis is almost entirely confined to 
restricted populations of cells within kidney and liver 
[3-5] where increased production is stimulated by re-
duced tissue oxygen delivery by a mechanism which · 
involves increased gene trdllScription [6,7). Interest bas 
therefore focussed on transcriptional control of the 
e[),thropoietin gene ac; a well-defined example of oxy-
gen regulated gene expression. 
The human hepatoma cell lines Hep:3B and HepG2 
have provided an appropriate model for studies of this 
system [8}. As with physiological induction of en·thro-
poietin production in the whole organism, erythropoi-
etin production by HepG2 and Hep3B in tissue culture 
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is induced by hypoxia or cobaltous ions, but not hy 
other stresses such as cyanide exposure or heat shock 
[8,9}. Transfection studies in these bepatoma cells have 
defined an oxygen-regulated enhancer commencing ap-
prox. 120 bp 3' to the poly(A) addition site of the 
human and mouse e.rythropoietin genes [10-14] . . The 
active enhancer sequence lies in a region of at least 150 
bp of striking homology betv.:een human and murine 
er;thropoietin gene loci and deletional analysis of the 
murine enhancer showed that approx. 60-70 bp were 
required for enhancer action when the sequence was 
placed 1.4 kb 5' to an a 1 globin reporter gene [12}. 
In further studies, we recently demonstrated that 
oxygen-regulated activity of a 96 nucleotide sequence 
from the mouse erythropoietin enhancer locus is not 
confined to the erythropoietin producing Hep3B and 
HcpG2 cells [15]. Hypoxia inducible operation of this 
sequence was demonstrated in a wide variety of mam-
malian cell types which are not do:!rived from liver or 
kidney and which do not produce erythropoietin. More 
detailed physiological analysis in one of these cell lines, 
the Chin~e hamster lung fibroblnstoid line, a23 (161, 
298 C.U~ Pugh et al. / Biochimica tt Biopliysica .·1cta 1217 (1994) J<Ji-306 
demonstrated that the features of erythropoietin regu-
_lation observed in bepatoma cells were reflected pre-
cisely in the operation of the transfected enhancer on a 
heterologous promoter (15]. Thus, enhancer action was 
induced by exposure to cobaltous ions as well as hy-
poxia, but not by cyanide, arsenite or heat shock. 
Induction was abrogated by cycloheximide. The irnpli· 
cation of these findings is that most mammalian cells 
possess an oxygen sensing and signal transduction sys- 1 
tern which is similar or identical to that which controls 
erythropoietin production in hepatoma cells, and which 
can interact with sequences within the mouse el)thro-
poietin enhancer. 
Precise definition of the sequences involved in that 
interaction is clearly of importance in further analysis 
of the system. To this end we have performed more 
detailed studies of the mouse el)1hropoietin enhancer 
using transfection· of deleted, mutated, and re-iterated 
sequences, and DNAse 1 protection analysis, to define 
the action of subsequences within the enhancer. Since 
the operation of an enhancer in different cell types 
may result from different DNA-protein interactions 
(17,18] we have perlormed these studies in different 
cell types; HepG2 cells, which produce el)1hropoietin 
and support regulated operation of the mouse el)thro-
poietin 3' enhancer, a23 cells which support regulated 
enhancer function but do not produce erythropoietin, 
and mouse erythroleukaemia (MEL) cells which previ-
ously [15] were the only cell type not to support oxy-
gen-regulated activity when using the 96 base pair 
enhancer sequence. 
Inducible activity in both el)1hropoietin producing 1 
and non-erythropoietin producing cell types was con· 
veyed by similar sequences and was dependent on two 
critical regions within the first 26 nucleotides of the 
mouse erythropoietin enhancer. When placed close to 
heterologous promoters apd when re-iterated, this 26 
nucleotide sequence was sufficient to convey inducible 
expression of reporter genes in all three cell types. 
Sequences lying 3' to this region could not operate in 
isolation but could modulate the inducible. response 1 
conveyed by the 5' sequences; both pos.itive and nega-
.tive effects were observed and differed according to 
the cell type. In HepG2 cells, 3' subsequences co-oper-
ated to permit operation of the enhancer at a distance 
from a promoter, but in l'v!EL cells 3' subsequences 
suppressed activity of the 5' subsequence. 
2. Materials and methods 
Cell lines and culture conditions 
HepG2 cells were grown in minimal essential 
medium with Earle's salts supplemented with 10% 
foetal calf serum, glutamine (2 mM), penicillin (50 
IU / ml) and streptomycin sulphate (50 µ g/ ml). a23 
cells [16] were grown in the same medium with the 
addition of sodium pyruvate (1 mM). MEL cells (lint 
585 [19]) were grown in RPJ\.H 1640 supplemented wi t! 
15% foetal calf serum, glutamate and antibiotics a'. 
above. 
Plasmid DNA 
After growth in Esclzericl1ia coli, plasmid DNA wa: 
prepared by alkaline lysis and purified on a cesiun-
gradient. Constructs containing deletions of the mous t 
erythropoietin enhancer linked to a 2570 bp BglU. 
PpuMI fragment containing the human a1 globin gem 
with 1.4 kb of 5' flanking sequence were made ir 
pBluescript SKII (Stratagene, Cambridge) as describec 
previously [12] (pBS a: - ). To assess the effects of dis· 
tance of the enhancer sequence from the promoter, the 
2570 bp a 1 globin fragment was exchanged for ar 
otherwise identical fragment which was deleted to po· 
sition -124 in the a: 1 glohin 5' flanking sequenc~ 
(pBSJa:). The enhancer nucleotides present in these 
plasmids were designated by numbers related to th~ 
first nucleotide of the Apal site at the 5' end of the 
enhancer (Fig. 1). 
Consecutive four base pair mutations of the erythro-
poictin enhancer, in which purines were substituted fo1 
their non-complementary pyrimidine and vice versa 
were made using the pALTER based Altered Sites ir. 
vitro mutagenesis system as directed by the manufac-
turers (Promega, Southampton). For these construc-
tions a 460 bp sequence containing the mouse crythro-
poietin enhancer was first ligated into pALTER. Muta-
genie oligonucleotides contained the four mutated nu-
cleotides flanked by ·14 complementary nucleotides or. 
each side. After retrieval of the mutant plasmid an c' 
confirmation of the mutation by dideoxy sequencing, f 
153 bp Bgll1-Pn1II fragmt:nt containing the mutatec 
erythropoietin enhancer region was subcloned intc 
polylinker sites in pBlucscript SK 11 which containec 
the 2570 bp a: 1 globin fragment described above 
(pBSa-). A similar plasmid containing the unmutatec 
153 bp Bglll-Pcull fragment from the erythropoietir 
enhancer locus was made to enable a direct cornpari· 
son of function between the wild type and mutatec 
enhancer sequences. · 
Further subsequences from within the erythropoi-
etin enhancer were derived either by PCR amplifka-
tion or by annealing synthesised oligonucleotides. Gen 
eration of concatamers and recombination of subse 
quences was facilitated by using oligonucleotides ir 
which compatible overhanging ends could be genera.tee 
from Xba I and Spe I restriction enzyme sites. These 
sequences were inserted adjacent to the SV40 pro 
moter in pSVGH. pSVGH contained a 198 bp Nsil 
HindIII fragment containing the SV40 early promote: 
sequence linked to human growth hormone (BamHI 
NsiI fragment) in pGEM7 (Promega, Southampton) 
• . 
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Fig. t. Deletional analysis of the mouse: erythropoietin eoh:i.ncer. (A) 
DNA sequence of the enhancer (E~ID!.. accessio~ number X73471) 
Nucleotides an: numbered from the fi~t base bf the Apal site. Test 
pl:ismids used in these c;{perimeots were based on the \·ector pBlue-
script SK 11. Sequence derived from the enhancer, (E) is 1.4 kb from 
the a 1 globin promoter (arrow). ll3) Effects of deletions on enhancer 
function in HepG2 cells and a23 cell~. Results for HepG2 indude 
~ome data derived from Puah et al. [12]. To pennit direct comp:irison 
of function, plasmids containing the truncated enhancer sequences 
~pecified, no enhancer and the: full length enhancer were transfec~d 
in parallc:1 into aliquots of cells from the same pool. Tramfected cells 
were dMded for parallel normo'Cic and bypQ,tlC incubation. In each 
transfection, expres.~ion o! the test plasmid was related to a co-tran!-
fec~d control plasmid (FGH). The results shown are the mcan±S.D. 
of at IC3St three independent transfections. No enhancer activity was 
obsel"lled in nonnoxic ceils. The deiTee of hypmcic induction con-
f('rred ~· truncated sequences from ·the enhancer is related to that 
conferred by the fuU length enhancer in each set ot e."{J)erimc:nts. In 
both HepG2 cells and a23 cells deletion of the nucl('utides !-3 
severe!; reduced enhancer function. More gradual loss of function 
was obs~d with deletions at the 3' end, where the effect of 
deletio~ differed between the cell types. 
Plasmids containfag no erythropoietin sequence 
(pSVGH) or the 168 bp KpnI-Nsil fragment containing 
the SV40 enhancer instead of erythropoietin sequence 
(pSVe SVGH) were used to provide a comparison with 
the activity of erythropoietin subsequences. 
A plasmid containing 290 bp of the promoter of the 
mouse ferritin heavy subunit gene fused to the human 
growth hormone gene (pFGH) was used to control for 
transfection efficiency in experiments where the test 
plasmid contained the a globin reporter gene. In ex-
periments where the test plasmid contained the growth 
hormone reporter gene. the a globin containing plas-
mid pBSa- was used to control for transfection effi-
ciency. 
Transfection atui incubation conditions 
Cells were transfected · by electroporation using a 1 
mF capacitor array charged at 375 V for HepG2 cells, 
400 V for a23 cells, and 425 V for .MEL cells. For each 
transfection, approx. 10 7 cells were mixed with control 
and test plasmid DNA in 1 ml of RP!vIT 1640. a 1 
globin plasmids were used at 50 µ.g/ml, pSVGH plas-
mids were used at 25 µ.g/ml and pFGH was used at 10 
µ.g/ml. After transfection the cell suspension was di-
vided for parallel 16 h nonnoxic and hypoxic incuba-
tions. Normoxic incubation was in humidified air with 
5% C0,2• Hypoxic incubation, commencing 1 h after 
electroporation was in 1 % 0 2 with 5% CO2 and 94% 
N2 in a Napco 7100 incubator. 
RNA analysis 
RNA was prepared using a modified acid/ 
guanidinium thiocyanate/ phenol/ chloroform extrac-
tion method (RNAzol B, Biogenesis, Bournemouth). 
Extracted RNA was assayed by Ri\lA<;e protection. 
Continuously labelled antisense riboprobes were gen-
erated from a 1 globin and growth hormone templates 
using the SP6 system. The growth honnone riboprobe 
crossed the boundaries of exon 3 and protected the 
entire 117 nucleotide sequence of th3,t exon. The a 1 
globin riboprobe crossed the cap site of the gene; 
different probes, which protected 97 or 132 nucleotides 
of exon 1, rel)'l)ective.ly, were used when the a 1 globin 
reporter gene was in the test plasmid, or the control 
plasmid. i 
In all assays 3-20 µ.g of total RNA was subject to 
double hybridisation with nooprobes for a I glob in and 
growth hormone. Protected fragments were separated 
by PAGE · and quantified by scintillation counting of 
excised portions of the dried gel using an LKB flat-bed 
~cintillation counter · (Phannacia-Wallac, Turku, Fin-
land). · 
; Each data point reported is the mean result of at 
least three independent transfection experiments. 
Nuclear extract preparation 
Nuclear extracts were prepart!d using a protocol 
derived from those of Dignam [20], and Kamaka.ka [21]. 
In outline, after parallel normoxic and hypoxic incuba-
tions, (1-5) · 107 cells were harvested using EDTA and 
resuspended in a hypotonic buffer (10 mM Na-Hepes, 
5 mM Mg 0 2, 10 mM KO, 0.5 mM DTT, 0.1 mM 
EDTA and 0.2 mM phenylmethylsulfonyl fluoride 
300 c.w: 1'11gh et al/ Biochimica er Biuphysicr1 .4cra 1117 (J.994j 107-306 
(PMSF)). Cells were then lysed by brief ultrasonication 
(10 Watts for 0.5 s, Soniprobe, Lucas Dawe Ultrason-
ics, London), such that > 85% took up Trypan blue. 
The nuclear pellet was mixed with an equal volume of 
extraction buffer (27 mNI Na-Hepes, 10 mM MgC1 1, 
300 mM KCI, 3.2 mM DTI, 0.1 mM EDTA, 1 mM 
benzamidine, 0.2 mM PMSF, 100 mM NaF, 1.33 µ.g/ml 
aprotinin, 0.2 µ.g/ml leupeptin, 0.2 µ.g/ml pepstatin, 
0.2 µ.g/ml bestatin and 16% glycerol) and agitated 
gently for 20 min at 4°C. The mix was ultracentrifuged 
at 100 000 X g for 30 min, the pellet and upper lipid 
layer were discarded and the clear supemat~mt, nor-
mally containing 6-10 µ.g / µ.l of protein, used directly 
as a nuclear extract or stored in liquid nitrogen. 
t 11 
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Fig. 2. Mutations define three critical rei:ions in nucleotides 1-48 of 
the mou~e erythropoietin enhancer. Mutations were made in a 1S3 
bp i Bg/II-A·uII fragment from the mouse erythropoietin enhancer 
loc1-1s which was placed 1.4 kb from the a 1 globin promoter (see Fig. 
1). ' Nucleotide substitutions are indicated. Plasmids containing the 
enhancer mutations, no enhancer and the unmutated enhaa,er were 
transfected in parallel into aliquots of cells from the same pool. 
Transfected cells were divided !or parallel normoxic and hypoxic 
incubation. No enhancer activity was observed in normo:<ic cells. 
Hypoxia inducible activity of the mutant enhancers is expressed as a 
percentage of that of the unmutated enhancer. Data shown are the 
mean± S.D. of three independent experiments. Mutations have simi-
lar effects on function in HepG2 cells and a23 cells. rn each cell type 
mutations of nucleotide 5-12, 21-24, and 33-44 caused Se\'ere 
reduction, or complete ablation, of function. lo HepG:? cells in· 
duciblc acth·ity of the unmutated enhancer was greater than in a23 
cells. values varying from 8-17 and 3-5. respectively. 
DNase/ protection assays 
Restriction fragments containing the erythropoieti 
enhancer region were selected such that either stran 
could be end-labelled by DNA polymerase I (Klena 
fragment) in the presence of [a-·12 P]dCTP and used , 
probes. Probe (1.5 · 10" cpm). approx. 50 mg of nucle: 
extract, and 0.5 µ.g of poly(dI/ dC) were incubated o 
ice for 15 min in 6% glycerol. The final concentratior 
of reagents in the 1reaction were 25 mM NaHepes, l. 
mM EDTA, 3.5 mM MgCI~ , 30 mM KC!, 10 mM NaI 
0.7 mM DTT, 0.2.5 mM PMSF, 5 mM benzamidine, 1 
mM glycerophosphate, 2 mM levamisole, 0.1 µ. g/ r; 
aprotinin, 0.1 ,ug/ml bestatin, 0.1 ,ug/ml lcupeptir 
and 0.1 J.Lg/ml pcpstatin. Titrations of DNaseI (typ 
IV from bovine pancreas, Sigma) diluted in lO mM Tr: 
(pH 8.0), were then added with CaCI, (2 mM fim 
concentration). After a 2 min incubation- on ice, 500 µ 
: of stop solution (O.:tl % SDS, 5.5 mM EDTA, and 33 
mM NaCl) was added. Samples wer~ extracted · wit 
phenol/ chloroform and chloroform, precipitated i: 
ethanol, and washed with 80% ethanol. Pellets wer 
redissolved in 80% formamide running buffer and sei: 
arated by denaturing PAGE prior to autoradiograph) 
3. Results 
Deletional analysis of tlze enhancer in different cell line. 
In previous experiments [12] we used construct 
which placed the mouse erythropoietin 3' enhancer l.· 
kb from the promoter of an a1 globin reporter gene tc 
detennine the mii;iimal enhancer sequence by dele 
tional analysis. These experiments in H;epG2 ce ll. 
demonstrated that 60-70 bp were required for fu l 
enhancer activity. As a first step in analysis of se 
quences required for enhancer function in differen 
cell lines, a similar deletional analysis was performec 
in a23 cells. Results arc shown in Fig. 1B. As with the 
HepG2 cells, active sequence was sharply delineatec 
close to the A.pal site at the 5' end of the enhancer 
but at the 3' end the boundary of active sequence wa. 
less clear. In cun~rast with HepG2 the sequence 1-8( 
appeared to be more active than sequence 1-96 in a2: 
cells, and a greater proportion of the full length en-
hancer activity was retained in the shorter 5' se-
quences. 
Mutational analysis of the enhancer region 
To identify critical regions within the enhancer, anc 
to compare these sites in different cell lines, systematic 
mutations were made in the 5' region of the enhancer 
which was necessarv for function in both HepG2 anc 
a23 cells. Thus. 12 · const:cutive four base pair muta-
tions were mad~ in the 48 bases lying 3' to the Apa I 
site. In each plasmid a 153 bp Bglll-PvuII restrictior 
fragment containing the mutated enhancer was ligatec 
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into the polylinker sequence of pBSa- lying 1.4 kb 5' 
to the a 1 globin reporter. Plasmids containing \'tild 
type and mutated sequences were then transiently 
transfected into HepG2 and a23 cells. In each transfec-
tion experiment, a single pool of cells was split to 
permit parallel transfections with plasmids containing 
no enhancer, the wild type enhancer and the mutated 
enhancers. After transfection, the cells were split for 
parallel normoxic and hypoxic incubations so that it 
was possible to compare directly the level of induction 
conveyed by wild type and mutant enhancer sequence. 
Results are shown in Fig. 2. In these plasmids, no 
constitutive action of the enhancer was observed in 
either a23 cells or HepG2 cells. Inducible activity !of 
the \vild type enhancer was greater in HepG2 than in 
a23 cells (8-17-fold compared ·with 3-5-fold), but the 
effect of mutation was very similar. In each cell type, 
nucleotides substitutions in three regions correspond-
ing to the mutations in plasmids 2-3, 6 and 9-11 
resulted in severe reduction of enhancer function. In 
contrast, mutations in plasmids 4, 5 and 7 had little 
effect on activity in either cell type. 
DNaseI protection analysis of the enhancer sequences 
To analyse further the structure of the enhancer 
DNaseI protection assays were performed using nu-
clear proteins extracted from aliquots of HepG2, a23 
cells, and ?,.,ffiL cells following parallel incubation un-
der normoxia and hypoxia. 
Fig. 3 shows the results obtained using a probe 
labelled 5' to the functionally defined sequence. Using 
nuclear extracts from HepG2 cells striking protection 
of nucleotides 28 to 49 was observed. This area was 
also protected when nuclear extract from a23 cells was 
used, although the protected region extended further 
3' and covered nucleotides 28 to 66. Nuclear extracts 
from l\.1EL produced a similar footprint but the protec-
tion was less complete. Addition of all nuclear extracts 
resulted in increased nuclease activity at nucleotide 23, 
when compared with the no extract lanes. Another 
area of protection was observed in the 5' region of the 
enhancer covering nucleotides -11 to 9 relative to the 
Apa! site. 
When equal concentrations of extracts from nor-
moxicaily and hypoxically incubated cells of each type 
were compared no change in the extent or degree of 
DNaseI protection was seen. 
Functional analysis of subsequences 
Since subsequences within enhancers may operate 
in isolation when placed close to a promoter or when 
re-iterated, further expression studies were performed 
using such elements placed immediately 5' to the SV40 
promoter. First the operation of elements consisting of 
nucleotides 1-26 and 25-60 was compared. 
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Fig. 3. DNAsel protection analysis of the mouse erythropoietin 
enhancer. The 5' end-labelled probe was a 484 bp Bglil-SphI 
fragment containing the mouse erythropoietin enhancer linked to 
polylinker sequence from pBluescript ·sKll. Nuclear extract was 
prepared after parallel 16 b incnbations of cells in normo:cia, 21 % 02 
(N) and hypoxia, 1 % O~ (H). Lane l, no extract; lanes 2 :ind 3, 50 µ.g 
of extract from normoxic and hypoxic HepG2 cells; lanes 4 and 5, 50 
µ.g of e:ttract from normoxic and hypo:tic a23 cells; lanes 6 and 7 70 
µ.g of extract from riormo:tic and hypoxic MEL cells. Lane 8 is a 
Maum and Gilbert G + A column from the same probe. The regions 
pr<Jtected are indicat~d using the numbering system shown in Fig. 1. 
defined by mutants 2-3 and 6, whereas nucleotides 
25-60 contain a direct repeat sequence TGA,C-
CTCITGACCC resembling a steroid/ thyroid receptor 
binding element and defined as functionally important 
by mutants 9-11 (see above). When expressed in 
HepG2 cells hypoxic expression was induced with the 
plasmids containing sequence 1-26 adjacent to the 
SV40 promoter but not \vith those containing sequence 
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Fig. 4. Actioa of subsequences from the mouse erythropoietin en· 
hancer on an adjacent SV40 promoter. The structure of the test 
plasmids is shown in (A). where E represents erythropoietin en· , 
hanccr sequence, SV40P represents the SV40 early promoter and 
GH represeat the body of the groYt1h hormone geae. The erythropoi-
etin enhancer sequence (E) used in each test plasmid is indicated 
beneath the corresponding bars of the histogram, numbered as in 
Fiii. 1. A co-transfected plasmid containing the a1 globin gene alone 
(pBSa:-) was used to correct for transfectioa efficiency. Expression 
t~ normalized to that of the enhancerless pSVGH iu normoxic cells 
and represents the mean± S.D. of three independent experiments 
CB). Inducible activity is conveyed by sequence 1-25 in all cell types. 
Inducible activity was much increased by concatamerization of this 
sequence which also conveyed some constitutive activity in normoxic 
cells Cl-2S}i and (1-25)5• In contrast, neither constitutive nor in-
ducible activity was conveyed by sequence (25-60) in nny cell type. 
Concatamers of this sequence were tested in either orientation 
(.25-60)3 and (60-25)~ but none had any action. The: monomeric 
sequence, 1-60. was more active than the monomeric sequence, 
1-25 in HepG2 cells and a23 but not MEL cells. 
25-60. This difference was most marked when con-
catamers of these sequences were compared. Re-itera-
tion of sequence 1-26 resulted in large increases in 
both normox.ic expression and in the amplitude of 
hypoxic induction, with expression in hypoxic HepG2 
exceeding that of the control plasmid containing the 
SV40 promoter alone by a factor approaching 100-fold. 
In contrast, re-iterations of sequence 25-60 produce 
no constitutive increase in expression in normox: 
HcpG2 cells and no inducible expression in hypoX.: 
HepG2 cells (Fig. 4B). 
When these plasmids were expressed in a23 cell 
the pattern of expression was very similar. Activi: 
resided in the sequence 1-26 but not in the sequenc 
25-60, although the level of induction was not as gre: 
as that observed in HepG2 cells (Fig. 4B). Tnteres 
ingly, when the constructs were expressed in MEL eel 
inducible activity was also observed. Again, activity w, 
conveyed by the sequence 1-26 but not sequence 25-c 
(Fig. 4B). 
Also of interest is comparison of the action of sc 
quence 1-60 with sequence 1-26 when placed adjacer 
to the SV40 promoter. In HepG2 cells a11d a23 cell 
there was an jncrease in the inducible activity of sc 
quence l-60 ...,:hen compared with sequence 1-26. Th: 
effect was not observed in MEL cells (Fig. 4). 
Since mutational analysis had indicated the exi~ 
tence of two critical regions within the sequence 1-2c 
short sequences including each of these sites wer 
inserted either as monomers or multimers adjacent t 
the SY40 promoter and expressed in HepG2 cells. Th 
two setgtenc.:es 4-15 and 16-27 were also rejoine 
using an S bp spacer (4-15) TCTAGTCC (16-27. 
None of these sequences conveyed activity when ex 
pressed in HepG2 cells (Table 1). 
Effect of distance from a promoter 
While both deletional and mutational analysis i: 
Hep 02 cells indi~ated that sequences 3' to nucleotid, 
26 were obligatory for enhancer function when th, 
sequence was placed 1.4 kb from the a 1 globin pro 
moter, these sequences were not obligatory and had nc 
activity in isolation when placed adjacent to an SV41 
promoter. To distinguish whether this difference was ; 
fundtion of distance from the promoter or some spe 
cific aspect of promoter sequence, exprt:ssion of plas 
mids containing subsequence 1-25 or subsequenc, 
1-96 approx. OJ .and 1.4 kb fro,n the a1 globin pro 
meter was compared. In HepG2 cells, sequence 1-9< 
was almost equally active in both positions wherea 
subsequence 1-25 was only active close to the pro 
Table 1 
Construct Constitutive Hypoxic/ Normoxic 
Control l .UU 1.46 
(4-15) 1.04 1.41 
(4-15)X2 0.69 1.40 
(-HS)X4 0.76 1.31 
(4-15Xl5-4) 0.76 1.39 
Cl5-4)X2 0.92 1.24 
(27-16)X2 0.87 0.91 
{16-27)X5 U.!!2 1.49 
(4-lS)NsU6-27) i.:u 0.92 
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Fig. 5. Effect of distance from a promoter on function of the mouse 
erythropoietin enhancer. The test plasmids which were used in these 
experiments are shown ;(A). The pai':s of plasmids were identical 
o:cept that one contained 124 bp of 5' flanking sequence from the 
a 1 globin gene and the other contained 1.4 kb of this sequence 
sepuating the enhancer from the a 1 globin promoter. A plasmid 
{FGH) was co-transfected to control for non-specific variation in 
transfection, .RNA synthesis and RNA recovery. Transfected cells 
were divided for parallel normoxic and hypoxic incubation. Normoxic 
and hypoxic e::q,ression of th~ test plasmid were normalised with 
respect to expression of the control plasm.id. The values plotted 
represent the ratio of normalised hypo:<ic to nonnoxic expression 
from ' three separate transfections (mean± S.DJ. In HepG2 cells 
nncleotides 25-96 were necessary for enhancer function at a distance 
from the a 1 i:lobin promoter but not when the enhancer was close to 
the promoter. In MEL cells nucleotides 1-96 had no constitutive or 
inducible activity when placed either near to or distant from the a 1 
globin promoter whereas inducible enhancer activity was observed 
with nucleotides 1-25, indicating that in this cell line nucleotides 
25-96 could suppress activity of the inducible element. · 
mater (Fig. SA). In MEL cell~ subsequence 1-25 was 
also active close to the promoter and retained a little 
activity at a distance. In contrast, sequence 1-96 was 
inactive in ?vt:EL cells whether it was near to or distant 
from the a 1 globin promoter (Fig. ?B), thus indicating 
the potential for regions within the sequence 25-96 to 
repress inducible activity in these cells. 
4. Discussion 
In this paper we present evidence for functionally 
distinct regions within the mouse erythropoietin 3' 
enhancer and show that similar sequences at the 5' 
portion of this enhancer are required in different cell 
lines for interaction with a widespread m.ygen sensing 
system. 
Deletion of sequence close to the Apa I site at the 5' 
end of the enhancer (construct 96-8, Fig. 1) sharply 
reduced enhancer actr.ity indicating that these eight 
nucleotides contained bases critical for inducible en-
hancer operation. However, the length of the minimal 
functional enhancer indicated that enhancer function 
was most probably dependent 9n several other critical 
sequences. This was borne out by the mutational analy-
sis of the first 48 nucleotides (Fig. 2) which defined 
three critical sites, corresponding to nucleotides 5-12, 
21-24 and 33-44. The sequences represented by nu-
cleotides 5-12 and 2~-24 d9 not have homology with 
known transcription factor binding motifs. Mutations 
affecting nucleotides 33-44 disrupt the sequence 
TGACCTCITGACCC which it has been suggested 
may represent a binding site for an orphan receptor of 
the steroid/thyroid hormone family [14]. 
The constructs used in these experiments contained 
the enhancer element separated from the a 1 globi.n 
promoter by 1.4 kb. All three regions within the en-
hancer were absolutely necessary for function in this 
setting. These sites might each convey inducible inter-
actions; alternatively some might simply play a permis-
sive role for enhancer function. Isolated sequences 
within enhancers which are inactive when placed at a 
distance from a promoter may operate when re-iterated 
or placed close to the promoter [18,22,23]. To test the 
subsequences individually for their ability to convey 
inducible responses we therefore placed monomers or 
concatamers of each ,element adjacent to the SV40 
promoter. 
1 
Concatamers of nuclebtide-s 1-26, which contained 
the 5' critical sites, but ' neither of the TGACCc / T 
half-sites, were compared directly with concatamers of 
nucleotides 25-60, containing the TGACCc / T direct 
. repeat. The behaviour of the two regions was quite 
different. Concatamers of nucleotides 1-26 were highly 
active and showed inducible activity which was substan-
tially · gTeater than even the full Iength enhancer. In 
contrast, neither monomers nor different concatamers . 
of nucleotides 25-60 showed any activity. The inde-
pendent operation of nucleotides 1-26 in the pSVGH 
plasmids was confirmed by the inducible operation of 
this sequence in pBS..:lal-25, which containeq a differ-
ent heterologous promoter and reporter gene. The two 
critical subsequences within this region indicated by 
mutation of nucleotides 5-12 and 21-24 did not ap-
pear to function independently since a variety of con-
catamers of nucleotides 4-15 or 15-27 were not func-
tional. Furthermore. introduction of spacing nu-
cleotides TCTAGTCC in construct 4-15(N8)16-27 ab-
lated function. Thus, these studies define the inducible 
operation of a 26 nucleotide sequence containing two 
sites which are critical for function. 
.~ 
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Two recent studies of the human enthropoietin 
enhancer have focussed on two different portions of 
the human enhancer, and have shown that mutations 
in each region can destroy enhancer function [13,14]. 
The region which we mutated in the mouse erythropoi-
etin enhancer was somewhat more extensive, and cov-
ered the regions which are homologous to both of 
those examined in the human studies. Despite the use 
of a different system of nucleotide substitution, the 
results of the current studies are entirely consistent 
with the experimental observations in each of the stud-
ies of the human enhancer. The critical regions defined 
by mutations 2-3 and 6 correspond to sequences desig-
nated BS-1 and BS-2 in one study [13], whereas muta-
tions 9-11 affect the directly repeated TGACCc / T 
half sites which were shown to be critical for function 
in the other study [14]. Thus, at least three functionally 
critical regions have been defined in the murine and 
human erythropoietin enhanc·ers. Different conclusions 
were reached in the two studies of the human en-
hancer as to the function of each region. Blancha.rd et 
al. [14] argued that the directly repeated half-sites were. 
the critical site of interaction, and postulated that 
modification of a factor at this site mediated the o;...,•-
gen regulated response. In contrast, Semenza and Wang 
[13] demonstrated an inducible DNA binding activity 
using an oligonucleotide from the 5' region of the 
enhancer, and found that a 33 bp oligonucleotide ex-
tending to include only 4 bp of one of the directly 
repeated half-sites retained some inducible activity 
which could be restored to the ,level shown by the full 
length enhancer by re-iteratlon. They postulated that 
the inducible interaction took place with sites at the 5' 
end of the enhancer ·with the : direct repeat element 
functioning to amplify the response. Our results, using 
a more extensive set of concatamerized subsequences 
from the murine erythropoietin enhancer support this 
interpretation. 
When the non-erythropoietin producing a23 cells 
are compared with HepG2 cells the same two critical 
sites were necessary for function in the 5' .region of the 
enhancer. Furthermore, in both HepG2 and a23 cells, 
sequences lying 3' to this region were important for 
operation at a distance, amplified the response wh~n 
the enhancer sequence was close to the promoter, but 
did not function independently. In our first report bf 
inducible operation of the mouse erythropoietin en-
hancer in non-erythropoietin producing cells [15], we 
performed physiological and pharmacological studies 
to show that the inducible response was distinct from 
other cell stress responses such as heat shock, and 
resembled the inducible response of the native erythro-
poietin gene in hepatoma cells. We therefore argued 
that a similar or identical mechanism of oxygen sensing 
and signal transduction must operate widely, most 
probably inducing the expression of other genes in 
non-erythropoietin producing cells. Such a system could 
induce gene expression by activation of a variety of 
transcription factors which might vary between differ-
ent cell types and recognize different . motifs in cis-
acting regulatory sequences [17,18]. Howt:ver, the cur-
rent demonstration that similar subsequences within 
the crythropoictin enhancer' arc critical for function in 
different cell lines strongly suggests that common fac-
tors are operating this response in different cell lines. 
In the DNAsel protection assays we did not observe 
inducible changes in protection of the critical se-
quences in the 5' region of the enhancer. Nor was 
DNAsel protection observed at similar sites in .recent 
analyses of the human erythropoietin enhancer [13]. 
However, using electrophoretic mobility shift assays, 
Semenza and Wang have observed inducible binding of 
a nuclear factor from Hep3B cells, which they qesig-
nated HTF-1, to nucleotides 3-2.l of the human en-
hancerjl3]. Our .results a.re therefore consistent with 
,the binding of such a factor to the mouse erythropoi-
etin enhancer and strongly suggest that it operates in 
other cell lines. Indeed, during the preparation of this 
manuscript, a paper reporting HlF-1 binding activity in 
a variety of mammalian cell lines in which the erythro-
poietin gene is not transcribed has been published [24]. 
Using nuclear extract from HepG2 cells in DNAseI 
footprinting studies striking non-inducible protection 
of nucleotides 29 to 50, which include the TGACCc / T 
repeat element, was observed. This footprint was closely 
similar to that described on the human enhancer using 
extract from .Hep3B cells (13,14]. However, a larger 
footprint extending o,·er a further 18 nucleotides 3' to 
this region was observed in a73 und MEL. Although 
this indicates differences in the DNA-protein interac-
tions with the 3' end of the enhancer it does not fully 
explain the functional data. For instance, deletion 
analysis in HepG2 cells implicated functionally impor-
tant sequences lying 3' to nucleotide SO which were 
necessary for enhancer operation at a distance, but 
which were not protected. It therefore appe:irs that, in 
addition to the TGACCc / T direct repeat, further sub-
sequences in the 3' region of the enhancer modulate 
the function of the inducible element. Precise defini-
tion of these sequences and their interactions will 
require further work. · 
One unexpected result was inducible operation via 
the 1-26 nucleotide sequence in MEL cells. These 
cells were the only cell type in our previous study [15] 
which was unable to support oxygen regulated reporter 
gene expression using plasmids containing the 1-96 
nucleotide enhancer sequence. This discrepancy was 
explained when inducible expression of the a 1 globin 
reporter was compared in different sets of plasmids 
containing nucleotides 1-25 and 1-96, showing that 
sequences in the region 25-96 could operate repres-
sively. Thus, although the sequences conveying in-
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ducible expression in the first 25 nucleotides of the 
enhancer appear to operate similarly in different cells 
the cunent studie; demonstrate the potential for mod-
ulatory effects to obscure the operation of the in-
ducible element in different cells. 
Although our previous studies indicated that the 
hypoxicatly inducible response was widespread in mam-
malian cells, failure to demonstrate inducible action in 
IvCEL suggested that the mechanism was not universal 
[it5]. It is clear from the current studies that in fact the 
inducible element can operate in MEL cells. Others 
have previously reported the absence of inducible re-
sponses in HeLa cells [10]. In the light of the above 
observations we have now tested these cells too and 
found inducible responses using constructs containing 
nucleotides 1-26. We have now tested nineteen cell 
lines (Ref. 15, this report and data not shown) and 
have yet to find one which does not have the capacity 
to modulate oxygen dependent ~hanges in reporter 
gene expression by ,the sequence 1-26. 
In addition to the promoters used in these experi-
ments, other transcriptionally active sequences from 
the SV40 enhancer, the herpes-simplex virus thymidine 
kinase gene promoter and the hypersensitive site 2 of 
the human f3 globin locus control region [25] do not 
show hypoxically inducible activity [11,12,15] (and data 
not shown) confirming the sequence specificity of this 
\\-idespread response. 
Based on responses obtained by exposure of hep-
atoma cells to transition elements, haem synthesis in-
hibitors, and haem protein ligands such as carbon 
monoxide, Goldberg et al. [9] proposed that the oxygen 
sdnsor controlling erythropoietin production by hep-
atoma cells might be a haem protein. The e:cistence 6f 
a similar mechanism of oxygen sensing in all the mam-
malian cells we have tested indicate-s that this mecha-
nism may well mediate oxygen-regulated expression of 
other genes in mammalian cells not specialized for the 
production of erythropoietin. It is also possible that the 
system is homologous with one or more of the oxygen 
sensing systems present in lower organisms, where the 
involvement of haem and haemoproteins in oxygen-
regulated gene e.""tpression is w,:II established [26-28]. 
In mammalian cells, the expression of several genes 
implicated in vascular growth is induced by hypoxia in 
a manner which resembles induction of erythropoietin 
gene expression in hepatoma cells. Platelet derived 
grov.rth factor f3 chain and endothelin expression is 
induced in hypoxic human umbilical vein endothelial 
cells [29,30]; as with the erythropoietin gene hypoxi-
cally induced expression was severely reduced by expo-
sure to carbon monoxide [29]. Expression of the vascu-
lar endothelial growth factor gene is induced by hy-
poxic e:-tposure in a variety of tissue culture cells; 
induction is sensitive to cycloheximide as is the case for 
induction of erythropoietin expression [31]. Oxygen 
regulated changes in gene expression also contribute to 
control of cellular metabolism. Expression of the genes 
for several glycolytic enzymes is induced by hypoxia, 
whereas expression of the gene for the gluconeogenic 
enzyme phosphoeno/pyruvate carboxykinase is reduced 
by hypoxia [32:-34]. This effect of hypoxia on phospho-
enolpyruvate carboxyk.inase gene expression is mim-
icked by cobalt at doses similar to those which induce 
erythropoietin gene expression [34]. 
The definition of the els-acting elements which are 
critical for interaction with the inducible system and 
the demonstration that the same sequences convey the 
interaction in non-ery1hropoietin producing cell lines 
should focus attempts to define and compare cir-acting 
sequence responsible for oxygen regulated expression 
of these other genes and to detect whether similar 
trans-acting mechanisms are indeed involved. 
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